

**Catalent Pharma Solutions, Inc. and Subsidiaries
and Predecessor**

Unaudited Consolidated and Combined Condensed Financial Statements

**As of December 31, 2007 and June 30, 2007,
And for the Three and Six Months Ended
December 31, 2007 and
December 31, 2006**

On April 10, 2007, certain businesses of the Pharmaceutical Technologies and Services segment of Cardinal Health, Inc. (the “Acquired Businesses”) were acquired by an entity controlled by affiliates of The Blackstone Group, a global private investment and advisory firm (“Blackstone”), pursuant to a Purchase and Sale Agreement dated as of January 25, 2007. This financial report presents the consolidated financial position, results of operations and cash flows of the Acquired Businesses as a stand-alone entity, Catalent Pharma Solutions, Inc. (the “Company” or the “Successor”) and the combined financial position, results of operations and cash flows of the Acquired Businesses as a segment of Cardinal Health, Inc. (the “Predecessor”)

As of the end of the period covered by this report, the Company was not subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. Consequently, this report has not and will not be filed with the Securities and Exchange Commission (“SEC”). However, the Company is obligated pursuant to its senior PIK-election note and senior subordinated note indentures, dated as of April 10, 2007, to post, on its website or provide to the Trustee, financial information that the Company would be required to file with the SEC were it subject to Sections 13 or 15(d) of the Securities Exchange Act of 1934, as amended, subject to exceptions consistent with the presentation of financial information in the Offering Memorandum, dated April 4, 2007, relating to the \$565,000,000 9 ½%/10¼% Senior PIK-Election Notes due 2015 and the €25,000,000 9 ¾% Senior Subordinated Notes due 2017 (the “Offering Memorandum”). This report is made available pursuant to such obligation.

**“Safe Harbor” Statement Under the
Private Securities Litigation Reform Act of 1995**

This financial report contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are not based on historical facts, but rather are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “foresee,” “likely,” “may,” “will,” “would” or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. Any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Risks and uncertainties include, but are not limited to general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs. Except as required by law, we do not intend to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Company’s historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in the Offering Memorandum.

Non-GAAP Financial Matters

In addition to disclosing financial results that are determined in accordance with U.S. GAAP, we disclose EBITDA and Adjusted EBITDA, which are non-GAAP measures. You should not consider EBITDA or Adjusted EBITDA as an alternative to operating or net earnings, determined in accordance with U.S. GAAP, as an indicator of our operating performance, or as an alternative to cash flows from operating activities, determined in accordance with U.S. GAAP, as an indicator of cash flows, or as a measure of liquidity. EBITDA is calculated by the sum of earnings before interest, taxes, depreciation and amortization.

Our credit facilities and the indentures governing our outstanding notes have certain covenants that use ratios utilizing a measure referred to as Adjusted EBITDA. The supplementary adjustments to EBITDA to derive Adjusted EBITDA may not be in accordance with current SEC practices or the rules and regulations adopted by the SEC that apply to periodic reports filed under the Securities Exchange Act of 1934. Accordingly, the SEC may require that Adjusted EBITDA be presented differently in filings made with the SEC than as presented in this release, or not be presented at all. The most directly comparable GAAP measure to EBITDA and Adjusted EBITDA is net earnings (loss). Included in this report is a reconciliation of earnings/(loss) to EBITDA and to Adjusted EBITDA.

We believe EBITDA and Adjusted EBITDA are measures commonly used by investors to evaluate our performance and that of our competitors. EBITDA and Adjusted EBITDA are not presentations made in accordance with U.S. GAAP and our use of the terms EBITDA and Adjusted EBITDA varies from others in our industry. EBITDA and Adjusted EBITDA should not be considered as alternatives to net income (loss), operating income or any other performance measures derived in accordance with U.S. GAAP as measures of operating performance or operating cash flows as measures of liquidity.

EBITDA and Adjusted EBITDA have important limitations as analytical tools and you should not consider them in isolation or as substitutes for analysis of our results as reported under U.S. GAAP. For example, EBITDA and Adjusted EBITDA:

- exclude certain tax payments that may represent a reduction in cash available to us;
- do not reflect any cash capital expenditure requirements for the assets being depreciated and amortized that may have to be replaced in the future;
- do not reflect changes in, or cash requirements for, our working capital needs; and
- do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on our debt.

Financial Statement Index

Unaudited Consolidated and Combined Financial Statements and Notes	
Condensed Statements of Operations	3
Condensed Balance Sheets	4
Condensed Statement of Changes in Equity	5
Condensed Statements of Cash Flows	6
Notes to Unaudited Consolidated and Combined Condensed Financial Statements	7 - 29
Management's Discussion and Analysis of Financial Condition and Results of Operations	30 - 46

UNAUDITED CONSOLIDATED AND COMBINED CONDENSED FINANCIAL STATEMENTS AND NOTES

**Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Consolidated and Combined Condensed Statements of Operations
(in millions)
Unaudited**

	Successor	Predecessor	Successor	Predecessor
	Three Months Ended December 31, 2007	Three Months Ended December 31, 2006	Six Months Ended December 31, 2007	Six Months Ended December 31, 2006
Net revenue	\$ 464.0	\$ 416.5	\$ 902.0	\$ 815.0
Cost of products sold	356.4	309.5	689.4	621.4
Gross margin	107.6	107.0	212.6	193.6
Selling, general and administrative expenses	84.2	73.8	158.5	148.1
Impairment charges and loss on sale of asset	-	0.9	0.4	3.1
Restructuring and other special items	9.0	5.9	13.3	8.0
Operating earnings	14.4	26.4	40.4	34.4
Interest expense, net	52.0	1.0	101.3	2.6
Other, net	10.6	(0.2)	19.8	-
Earnings/(loss) from continuing operations before income taxes and minority interest	(48.2)	25.6	(80.7)	31.8
Income tax benefit	(19.6)	(4.1)	(44.0)	(3.8)
Minority interest expense, net of tax expense (benefit) of \$(0.2) million, \$(1.6) million, \$(0.1) million and \$(1.8) million, respectively	0.6	2.0	0.3	2.2
(Loss)/earnings from continuing operations	(29.2)	27.7	(37.0)	33.4
Loss from discontinued operations, net of tax expense (benefit) of \$(0.2) million, \$3.6 million, \$0.5 million and \$1.1 million, respectively	(1.0)	(9.2)	(4.5)	(13.8)
Net (loss)/earnings	\$ (30.2)	\$ 18.5	\$ (41.5)	\$ 19.6

The accompanying notes are an integral part of these consolidated and combined condensed financial statements

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Consolidated Condensed Balance Sheets
(in millions, except shares)
Unaudited

	December 31,	June 30,
	2007	2007
ASSETS		
Current assets:		
Cash and equivalents	\$ 59.5	\$ 82.7
Trade receivables, net	294.4	310.3
Receivables due from Cardinal Health, Inc. and affiliates	11.2	13.7
Inventories, net	218.4	218.9
Prepaid expenses and other	70.1	68.3
Assets held for sale	73.9	82.3
Total current assets	727.5	776.2
Property and equipment, net	1,050.9	1,056.1
Other assets:		
Goodwill	1,467.7	1,421.7
Other intangibles, net	526.1	546.3
Other	60.0	62.0
Total assets	\$ 3,832.2	\$ 3,862.3
LIABILITIES AND SHAREHOLDER'S EQUITY		
Current liabilities:		
Current portion of long-term obligations and other short-term borrowings	\$ 48.7	\$ 36.4
Accounts payable	115.2	114.6
Other accrued liabilities	184.8	174.5
Liabilities held for sale	26.4	36.1
Total current liabilities	375.1	361.6
Long-term obligations, less current portion	2,324.1	2,275.6
Pension liability	81.1	106.1
Deferred income taxes	113.9	171.5
Other liabilities	34.4	36.9
Commitment and contingencies (see Note 13)		
Shareholder's equity:		
Common stock \$0.1 par value; 1,000 shares authorized, 100 shares issued	-	-
Additional paid in capital	1,068.0	1,049.9
Accumulated deficit	(191.8)	(150.3)
Accumulated other comprehensive income	27.4	11.0
Total shareholder's equity	903.6	910.6
Total liabilities and shareholder's equity	\$ 3,832.2	\$ 3,862.3

The accompanying notes are an integral part of these consolidated and combined condensed financial statements

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Consolidated Condensed Statement of Changes in Shareholder's Equity
(in millions)
Unaudited

	Common Stock	Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income/(Loss)	Total Shareholder's Equity
Successor					
Balance June 30, 2007	\$ -	\$ 1,049.9	\$ (150.3)	\$ 11.0	\$ 910.6
Equity contribution		14.1			14.1
Comprehensive income/(loss):					
Net loss			(41.5)		
Foreign currency translation adjustments				33.6	
Change in unrealized gain/(loss) on derivatives				<u>(17.2)</u>	
Total comprehensive loss					(25.1)
Equity compensation		4.0			4.0
Balance at December 31, 2007	<u>\$ -</u>	<u>\$ 1,068.0</u>	<u>\$ (191.8)</u>	<u>\$ 27.4</u>	<u>\$ 903.6</u>

The accompanying notes are an integral part of this consolidated condensed financial statement

**Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Consolidated and Combined Condensed Statements of Cash Flows**

(in millions)

Unaudited

	<u>Successor</u>	<u>Predecessor</u>
	<u>Six Months</u>	<u>Six Months</u>
	<u>Ended</u>	<u>Ended</u>
	<u>December 31,</u>	<u>December 31,</u>
	<u>2007</u>	<u>2006</u>
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net (loss)/earnings	\$ (41.5)	\$ 19.6
Loss from discontinued operations	(4.5)	(13.8)
Loss/earnings from continuing operations	(37.0)	33.4
Adjustments to reconcile loss/earnings from continued operations to net cash from operations:		
Depreciation and amortization	82.3	48.3
Amortization of debt financing costs	3.7	-
Minority interest (income)/ expense	0.3	2.2
Non-cash restructuring and other special items	0.9	0.5
Asset impairments and loss on sale of assets	0.4	3.0
Equity compensation	4.0	13.4
Benefit for deferred income taxes	(60.2)	0.2
Provisions/ (recoveries) for bad debts and inventory	5.5	1.7
Change in operating assets and liabilities:		
Decrease in trade receivables	15.3	21.8
Increase in inventories	(4.4)	(4.1)
Decrease in accounts payable	(1.3)	(5.6)
Other accrued liabilities and operating items, net	(44.6)	(32.3)
Net cash (used in)/ provided by operating activities from continuing operations	(35.1)	82.5
Net cash used in by operating activities from discontinued operations	(0.8)	(0.5)
Net cash (used in)/ provided by operating activities	(35.9)	82.0
CASH FLOWS FROM INVESTING ACTIVITIES:		
Proceeds from sale of assets	0.3	11.7
Additions to property and equipment	(37.5)	(33.5)
Net cash used in investing activities from continuing operations	(37.2)	(21.8)
Net cash used in investing activities from discontinuing operations	(1.1)	(1.8)
Net cash used in investing activities	(38.3)	(23.6)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Net change in short-term borrowings	15.2	(1.6)
Repayments of long-term obligations	(11.8)	(4.8)
Proceeds from long-term obligations	-	4.5
Equity contribution	14.1	-
Net transfers to Cardinal Health, Inc. and affiliates	-	(28.4)
Net cash provided by/ (used in) financing activities from continuing operations	17.5	(30.3)
Net cash provided by/(used in) from discontinued operations	-	-
Net cash provided by/(used in) financing activities	17.5	(30.3)
Effect of foreign currency	33.5	4.7
NET (DECREASE)/ INCREASE IN CASH AND EQUIVALENTS	(23.2)	32.8
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD	82.7	133.6
CASH AND EQUIVALENTS AT END OF PERIOD	\$ 59.5	\$ 166.4
SUPPLEMENTARY CASH FLOW INFORMATION:		
Interest paid	\$ 99.2	\$ -
Taxes paid	\$ 11.5	\$ -

The accompanying notes are an integral part of these consolidated and combined condensed financial statements

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business

Catalent Pharma Solutions, Inc. (“Catalent”, the “Company, or the “Successor”) is a direct wholly-owned subsidiary of PTS Intermediate Holdings LLC (“Intermediate Holdings”). Intermediate Holdings is a direct wholly-owned subsidiary of PTS Holdings Corp. (“Parent”) and Parent is 100% owned by Phoenix Charter LLC (“Phoenix”) and certain members of the Company’s senior management. Phoenix is wholly-owned by BHP PTS Holdings LLC, an entity controlled by affiliates of The Blackstone Group (“Blackstone”), a global private investment and advisory firm.

Basis of Presentation

On April 10, 2007, certain businesses owned by Cardinal Health, Inc. (“Cardinal”) and operated as part of Cardinal’s Pharmaceutical Technologies and Services (“PTS”) segment (the “Acquired Businesses”), were acquired by an entity controlled by affiliates of Blackstone, pursuant to a Purchase and Sale Agreement dated as of January 25, 2007 entered into between Phoenix and Cardinal (the “Purchase Agreement”).

These condensed financial statements are unaudited and should be read in conjunction with the Company’s audited consolidated and combined financial statements and related notes as of June 30, 2007 and June 30, 2006 and for the periods April 10, 2007 to June 30, 2007 and July 1, 2006 to April 9, 2007 and for the Two Years Ended June 30, 2006. In the opinion of management, all adjustments necessary for a fair presentation have been included. Except as disclosed elsewhere in this interim report, all adjustments are of normal recurring nature. The results reported in these condensed financial statements should not be taken as indicative of results that may be expected for the entire year.

These unaudited condensed financial statements as of and for the three and six months ended December 31, 2007, present the consolidated financial position, results of operations and cash flows of the Successor as a stand-alone entity and the combined financial position, results of operations and cash flows of the Acquired Businesses when operated as part of the Pharmaceutical Technologies and Services (“PTS”) segment of Cardinal (hereinafter, the “Predecessor”), as of and for the three and six months ended December 31, 2006, including adjustments, allocations and related party transactions and have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The unaudited condensed financial statements as of December 31, 2007 and for the three and six months ended December 31, 2007 include the financial condition, results of operations and cash flows for the Company on a successor basis, and the impact of the preliminary purchase price allocation. These unaudited condensed financial statements include the accounts of the Company and all of its subsidiaries. All inter-company transactions have been eliminated. Certain items have been reclassified in the Company’s audited consolidated and combined financial statements as of June 30, 2007 to conform to the current period presentation.

The Predecessor’s unaudited financial statements were derived from the consolidated financial statements of Cardinal using the historical results of operations and the historical basis of assets and liabilities of the Predecessor. The Predecessor unaudited condensed financial statements presented may not be indicative of the results that would have been achieved had the Predecessor operated as a separate, stand-alone entity.

During Q2 fiscal 2008, the Company identified a prior period error at one of its European Oral Technologies segment’s facilities of approximately \$11.0 million which consists of a non-cash charge of approximately \$10.0 million. The error identified primarily relates to the overcapitalization of costs in inventory and overstatement of engineering spare parts. The Company has concluded that the error is not material to any prior annual or interim period or to the expected fiscal year 2008 financial position or results of operations and accordingly, the Company has recorded a charge to cost of goods sold totaling \$11.0 million in the Q2 fiscal 2008 results of operations within its Oral Technologies segment.

Allocation of Cardinal Costs

The financial statements for the Predecessor periods include all costs of the Predecessor and certain costs allocated from Cardinal. Cardinal provided various services to the Predecessor, including but not limited to cash management, tax and legal services, information technologies services, internal audit, facilities management, security, payroll and employee benefit administration, insurance administration, and telecommunication services. Cardinal allocated these expenses and all other central operating costs, first on the basis of direct usage when identifiable, with the remainder allocated among Cardinal’s

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

businesses on the basis of their respective revenues, headcount or other measure. In the opinion of management, these methods of allocating costs are reasonable.

The financial statements for the Predecessor periods are not intended to be a complete presentation of the financial position, results of operations and cash flows as if the Predecessor had operated as a stand-alone entity during those periods presented. Had the Predecessor existed as a stand-alone entity, its financial position, results of operations and cash flows could have differed materially from those included in the financial statements included herein. In addition, the future financial position, results of operations and cash flows could differ materially from the historical results presented.

Cardinal used a centralized approach to cash management and the financing of operations. Cash deposits from the Predecessor were transferred to Cardinal on a regular basis within the United States and were netted against Cardinal's net investment account. Similarly, settlements of intercompany interest and income taxes were paid through the Cardinal net investment account. None of Cardinal's cash, cash equivalents or debt were allocated to the Predecessor in the financial statements.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles ("GAAP") in the United States requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, inventory valuation, goodwill and other intangible asset impairments, equity-based compensation, income taxes, self insurance accruals, loss contingencies and restructuring charge reserves. Actual amounts may differ from these estimated amounts. Some of the more significant estimates used include those used in accounting for the Acquisition under the purchase method of accounting, and prior to the acquisition, in allocating certain costs to the Predecessor in order to present the Predecessor's operating results on a stand alone basis.

There were no significant changes to these policies or in the underlying accounting assumptions and estimates used in the Company's critical accounting policies from those disclosed in the Company's Fiscal 2007 Consolidated and Combined Financial Statements.

Recent Financial Accounting Standards

In February 2006, the FASB issued SFAS No. 155, "Accounting for Certain Hybrid Financial Instruments," an amendment of SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities" and SFAS No. 140, "Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities." This Statement permits fair value remeasurement for any hybrid financial instrument that contains an embedded derivative that would otherwise be required to be bifurcated from its host contract. The election to measure a hybrid financial instrument at fair value, in its entirety, is irrevocable and all changes in fair value are to be recognized in earnings. This Statement also clarifies and amends certain provisions of SFAS No. 133 and SFAS No. 140. This Statement is effective for all financial instruments acquired, issued or subject to a remeasurement event occurring in fiscal years beginning after September 15, 2006. Early adoption is permitted, provided the Company has not yet issued financial statements, including financial statements for any interim period, for that fiscal year. The adoption of this Statement did not have a material impact on the Company's financial position or results of operations.

In July 2006, the FASB issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes." This Interpretation prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. While this Interpretation is generally effective for fiscal years beginning after December 15, 2006, the FASB has deferred this effective date for nonpublic enterprises to fiscal years beginning after December 15, 2007. However the Company has adopted the provisions of FIN 48 effective July 1, 2007. The cumulative effects, if any, of applying this Interpretation will be recorded as an adjustment to accumulated deficit as of the beginning of the period of adoption. The adoption of this Interpretation did not have a material impact on the Company's financial position or results of operations (see Note 8 for further discussion).

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements." This Statement defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. This

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

Statement is effective for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company is in the process of determining the impact of adopting this Statement.

In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities.” SFAS No. 159 permits an entity, on a contract-by-contract basis, to make an irrevocable election to account for certain types of financial instruments and warranty and insurance contracts at fair value, rather than historical cost, with changes in the fair value, whether realized or unrealized, recognized in earnings. SFAS No. 159 is effective for the Company in the first quarter of fiscal 2009. The Company is in the process of determining the impact of adopting this Statement.

In June 2007, the Emerging Issues Task Force reached a consensus on Issue No. 07-3, *Accounting for Nonrefundable Advance Payments for Goods or Services Received for Use in Future Research and Development Activities*. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. Such amounts should be recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided. This Issue is effective for financial statements issued for fiscal years beginning after December 15, 2007, and earlier application is not permitted. This consensus is to be applied prospectively for new contracts entered into on or after the effective date. The Company is evaluating the potential impact of this consensus and does not expect it to have a material effect on its consolidated financial statements.

In December 2007, the FASB issued SFAS No. 141 (revised 2007), “Business Combinations.” SFAS No. 141R establishes principles and requirements for how the acquirer in a business combination recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed and any non-controlling interest in the acquiree at the acquisition date fair value. SFAS No. 141R determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. SFAS No. 141R applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. Early adoption is not permitted.

In December 2007, the Securities and Exchange Commission (“SEC”) issued Staff Accounting Bulletin No. 110 (“SAB 110”). SAB 110 amends and replaces Question 6 of Section D.2 of Topic 14, *Share-Based Payment*. SAB 110 expresses the views of the staff regarding the use of the “simplified” method in developing an estimate of expected term of “plain vanilla” share options in accordance with FASB Statement No. 123(R), *Share Based Payment*. The use of the “simplified” method was scheduled to expire on December 31, 2007. SAB 110 extends the use of the “simplified” method for “plain vanilla” awards in certain situations. The Company currently uses the “simplified” method to estimate the expected term for share option grants as it does not have enough historical experience to provide a reasonable estimate due to the limited period the Company’s equity shares have been publicly traded. The Company will continue to use the “simplified” method until it has enough historical experience to provide a reasonable estimate of expected term in accordance with SAB 110. SAB 110 is effective for options granted after December 31, 2007.

On December 4, 2007, the FASB issued SFAS No. 160, *Noncontrolling Interests in Consolidated Financial Statements* (SFAS 160). SFAS 160 is an amendment of Accounting Research Bulletin (ARB) No. 51 and was issued to improve the relevance, comparability, and transparency of the financial information that a reporting entity provides in its consolidated financial statements. This Statement applies to all entities that prepare consolidated financial statements, except not-for-profit organizations, but will affect only those entities that have an outstanding noncontrolling interest in one or more subsidiaries. SFAS 160 clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements and that a parent company must recognize a gain or loss in net income when a subsidiary is deconsolidated. SFAS 160 is effective for fiscal years beginning after December 15, 2008 and early adoption is prohibited. The Company is currently evaluating the potential impact on its statement of financial position and results of operations.

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

2. THE ACQUISITION

On January 25, 2007, Phoenix, a newly formed Delaware limited liability company that is controlled by affiliates of Blackstone, entered into the Purchase Agreement with Cardinal to purchase the issued and outstanding shares of capital stock of certain entities controlled by Cardinal and specified related receivables, which together comprised the Predecessor, for an aggregate purchase price of approximately \$3.3 billion, as adjusted pursuant to certain provisions in the Purchase Agreement for working capital, cash, indebtedness and earnings before interest, taxes and depreciation and amortization expense of the Successor and a pension adjustment associated with an under funded pension liability of approximately \$70.0 million. Phoenix subsequently assigned its rights and obligations under the Purchase Agreement to PTS Acquisition Corp., Phoenix's indirect and wholly owned subsidiary, which entity effected the acquisition. In these financial statements, we refer to this acquisition as the "Acquisition." The Acquisition was consummated on April 10, 2007.

The Acquisition was part of a series of transactions which occurred simultaneously on April 10, 2007 (except as discussed below) and included:

- a cash contribution of approximately \$1.0 billion from Phoenix to PTS Holdings Corp., an entity controlled by affiliates of Blackstone and Phoenix's direct subsidiary, in exchange for common stock, which amount was in turn contributed to PTS Intermediate Holdings LLC, a direct wholly owned subsidiary of Phoenix, which amount was in turn contributed to PTS Acquisition Corp., and which PTS Acquisition Corp. used to fund the equity portion of the purchase price and which contribution is reflected in the Company's Equity on its Balance Sheet as of June 30, 2007;
- the issuance of senior toggle notes and senior subordinated notes by PTS Acquisition Corp. for proceeds in the amount of \$565.0 million and \$300.3 million in proceeds, respectively;
- the entering into a new senior credit facility by PTS Acquisition Corp. and the related receipt of approximately \$1.4 billion in proceeds under the credit facility;
- the payment of other fees and expenses in connection with the Acquisition;
- immediately following the Acquisition on April 10, 2007, the merger of PTS Acquisition Corp. with and into Cardinal Health 409, Inc.; and
- the surviving entity, Cardinal Health 409, Inc., was subsequently renamed as Catalent Pharma Solutions, Inc., and is referred to herein as "Catalent", the "Successor", or the "Company".

Costs associated with issuing the long term debt obligations above approximated \$56.3 million and are capitalized on the Company's balance sheet and are amortized to interest expense over the respective terms of the debt instruments.

The Company is in the process of finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. A valuation study was performed which supports the Company's purchase price allocation. The valuation study resulted in (i) a fair value step-up to real and personal property and certain identifiable intangible assets, (ii) an increase in the value of inventory and a corresponding charge to cost of products sold related to higher costs of inventory sold during the period April 10, 2007 to June 30, 2007; and (iii) recording and writing off acquired in-process research and development ("IPR&D"), which was subsequently charged to expense in fiscal 2007.

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

The Company anticipates that purchase accounting for the Acquisition will be finalized by the third quarter of fiscal 2008. The excess of the purchase price paid over the fair value of the net assets acquired and liabilities assumed has been allocated to goodwill. Intangible assets with indefinite lives consist of amounts related to the Company's assembled workforce, which was calculated as part of the Acquisition valuation study, is not being amortized and is included in goodwill on the Company's balance sheet. Of the total excess purchase price attributable to goodwill, \$145.0 million is deductible for tax purposes. The following table summarizes the preliminary allocation of fair values of the Company's assets acquired and liabilities assumed at the date of acquisition.

(in millions)	<u>April 10, 2007</u>
Current assets	\$ 707.0
Property and equipment	1,055.2
Intangible assets	556.3
In-process research and development	112.4
Other assets	64.4
Total assets	<u>2,495.3</u>
Current liabilities	(266.2)
Long term debt	(2,271.4)
Non current liabilities	(135.9)
Deferred taxes	(193.3)
Total liabilities	<u>(2,866.8)</u>
Equity contributions	<u>(1,048.9)</u>
Excess purchase price attributable to goodwill	<u>\$ 1,420.4</u>

The following table summarizes the preliminary allocation of the Acquisition purchase price:

(in millions)	<u>April 10, 2007</u>
Purchase price allocation:	
Purchase price	\$ 3,216.5
Transaction fees and expenses	69.1
Total purchase price	<u>3,285.6</u>
Less:	
Net tangible assets acquired	1,292.7
Fair value adjustment to inventory	29.4
Fair value adjustment to property and equipment	16.8
Other intangible assets acquired	556.3
In-process research and development	112.4
Net assets held for sale	50.9
Deferred income tax liabilities	(193.3)
Excess purchase price attributable to goodwill	<u>\$ 1,420.4</u>

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

The following unaudited pro forma data for the Acquisition includes the results of operations as if the Acquisition had been consummated as of the beginning of the Predecessor period presented. This pro forma data is based on the Predecessor's historical information and does not necessarily reflect the actual results that would have occurred, nor is it indicative of future results of operations.

	<u>Historical</u>	(unaudited)	
	<u>As Reported</u>	For the three months ended	
		<u>December 31, 2006</u>	
		<u>Adjustments</u> ⁽¹⁾	<u>Pro Forma</u>
Net revenues	\$ 416.5	\$ -	\$ 416.5
Earnings/(loss) from continuing operations before income taxes and minority interest	25.6	(62.9)	(37.3)

	<u>Historical</u>	(unaudited)	
	<u>As Reported</u>	For the six months ended	
		<u>December 31, 2006</u>	
		<u>Adjustments</u> ⁽¹⁾	<u>Pro Forma</u>
Net revenue	\$ 815.0	\$ -	\$ 815.0
Earnings/(loss) from continuing operations before income taxes and minority interest	31.8	(267.1)	(235.3)

- (1) Includes adjustments in the six months ended December 31, 2006 related to charges for in-process research and development and the higher inventory costs, and for the three and six months ended December 31, 2006 charges for the annual advisory fee that we expect to pay to The Blackstone Group, increased amortization and depreciation expense based on the fair values for recording of the Acquisition, and in addition, the incremental interest expense and amortization of deferred financing fees related to the debt incurred in connection with the Acquisition.

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

3. DISCONTINUED OPERATIONS AND DIVESTITURES

Discontinued Operations

In connection with the Acquisition, the Company made a determination and initiated plans to dispose of its Albuquerque, New Mexico, and Osny, France operations. These two businesses are classified as held for sale on the Company's balance sheet and included in discontinued operations on the Company's statement of operations and cash flows. During the three months ended December 31, 2007, the Company made a determination to write down the assets of Albuquerque, New Mexico operations by \$5.0 million. Summarized statements of operations data for these discontinued operations are as follows:

	Successor	Predecessor	Successor	Predecessor
	Three Months Ended December 31, 2007	Three Months Ended December 31, 2006	Six Months Ended December 31, 2007	Six Months Ended December 31, 2006
Net revenues	\$ 23.9	\$ 24.5	\$ 45.9	\$ 47.0
Loss before income taxes	(1.2)	(5.6)	(4.0)	(12.7)
Income tax expense/(benefit)	(0.2)	3.6	0.5	1.1
Loss from discontinued operations, net of tax	\$ (1.0)	\$ (9.2)	\$ (4.5)	\$ (13.8)

Summarized balance sheet data for these discontinued operations is as follows:

(in millions)	December 31, 2007	June 30, 2007
Assets held for sale		
Current assets	\$ 45.4	\$ 53.0
Property and equipment	28.5	29.3
Total assets held for sale	<u>\$ 73.9</u>	<u>\$ 82.3</u>
Liabilities held for sale		
Current liabilities	\$ 26.4	\$ 35.3
Other liabilities	-	0.8
Total liabilities held for sale	<u>\$ 26.4</u>	<u>\$ 36.1</u>

Divestitures

Under the Predecessor, the Company sold one of its facilities within the Oral Technologies segment to Adams Respiratory Operations, Inc. on July 31, 2006. The terms of the sale included the sale of assets of the facility and resulted in a loss on sale of assets of \$1.0 million recorded in the "impairment charges and (gain)/loss on sale of assets" within the statements of operations. In accordance with Emerging Issue Task Force Issue No. 03-13, "Applying the Conditions in Paragraph 42 of SFAS No. 144 in Determining Whether to Report Discontinued Operations" ("EITF 03-13"), the results of operations of this sold facility have not been reclassified to discontinued operations because the Company will continue to receive significant cash inflows from the products associated with this facility.

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

4. GOODWILL

The following table summarizes the changes between June 30, 2007 and December 31, 2007, in the carrying amount of goodwill in total and by reporting segment:

(in millions)	Oral Technologies	Sterile Technologies	Packaging Services	Total
Balance at June 30, 2007	\$ 718.7	\$ 452.5	\$ 250.5	\$ 1,421.7
Purchase accounting adjustments	4.8	3.0	1.7	9.5
Foreign currency translation adjustments	18.1	15.7	2.7	36.6
Balance at December 31, 2007	\$ 741.6	\$ 471.1	\$ 254.9	\$ 1,467.7

5. OTHER INTANGIBLE ASSETS

Other intangible assets with definite lives are being amortized using the straight-line method over periods that range from twelve to twenty years. The details of other intangible assets subject to amortization by class as of December 31, 2007 and June 30, 2007, are as follows:

(in millions)	Weighted Average Life	Gross Intangible	Accumulated Amortization	Net Intangible
December 31, 2007				
Amortized intangibles:				
Core technology	20.0 years	\$ 153.4	\$ (5.7)	\$ 147.7
Customer relationships	12.0 years	148.9	(9.3)	139.6
Product relationships	12.0 years	254.0	(15.2)	238.8
Total amortized intangible assets	13.5 years	\$ 556.3	\$ (30.2)	\$ 526.1

(in millions)	Weighted Average Life	Gross Intangible	Accumulated Amortization	Net Intangible
June 30, 2007				
Amortized intangibles:				
Core technology	20.0 years	\$ 153.4	\$ (1.9)	\$ 151.5
Customer relationships	12.0 years	148.9	(3.1)	145.8
Product relationships	12.0 years	254.0	(5.0)	249.0
Total amortized intangible assets	13.5 years	\$ 556.3	\$ (10.0)	\$ 546.3

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

Amortization expense for the three and six months ended December 31, 2007 was approximately \$10.3 million and \$20.6 million, respectively, and the three and six months ended December 31, 2006, was approximately \$0.4 million, and \$0.7 million, respectively. Amortization expense is estimated to be:

(in millions)	Remainder fiscal 2008	fiscal 2009	fiscal 2010	fiscal 2011	fiscal 2012
Amortization expense	\$ 20.6	\$ 41.2	\$ 41.2	\$ 41.2	\$ 41.2

6. RESTRUCTURING AND OTHER SPECIAL ITEMS

Restructuring and Other Special Items Accrual Roll forward

During the six months ended December 31, 2007, the Company recorded termination lease costs related to the previously announced closure of one of our Sterile Technologies manufacturing facilities, as well as additional separation costs incurred as a result of the Acquisition.

The following table summarizes activity related to liabilities associated with special items:

(in millions)	Successor Six Months Ended December 31, 2007
Balance at beginning of period	\$ 8.2
Additions	7.7
Payments	(8.7)
Balance at end of period	\$ 7.2

7. LONG-TERM OBLIGATIONS AND OTHER SHORT-TERM BORROWINGS

As of December 31, 2007, the Company had \$30.0 million of net borrowings outstanding under its Revolving Credit Agreement. At the end of June 2007, the Company entered into interest rate swaps, expiring June 2010, as a derivative instrument to manage the risk associated with the Company's floating rate debt. The unrealized loss on hedge instruments of \$17.2 million is recorded within Accumulated Other Comprehensive Income on the Company's consolidated balance sheet at December 31, 2007.

8. INCOME TAXES

The Company's (benefit)/ expense for income taxes relative to earnings (loss) from continuing operations before income taxes and minority interest was (54.6%) for the six months ended December 31, 2007, as compared to (12.0%) for the six months ended December 31, 2006. Generally, fluctuations in the effective tax rate are primarily due to changes in the U.S. and non-U.S. pretax income resulting from the Company's business mix and changes in the tax impact of special items and other discrete tax items, which may have unique tax implications depending on the nature of the item. In the normal course of business, we are subject to examination by taxing authorities throughout the world, including such major jurisdictions as Germany, U.K. and France. The benefit for the six months ended December 31, 2007 includes adjustments in the Company's deferred tax liabilities for tax rate changes in Germany, UK and Italy of \$5.5 million, \$3.9 million and \$0.4 million, respectively. With few exceptions, we are no longer subject to non-U.S. income tax examinations for years prior to 2001. Under the terms of the purchase agreement related to the Acquisition, the Company is indemnified by Cardinal for tax liabilities that may arise in the future that relate to tax periods prior to April 10, 2007. The indemnification agreement includes,

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

among other taxes, any and all Federal, state and international income based taxes as well as interest and penalties that may be related thereto. Approximately \$4.9 million of unrecognized tax benefits and related interest is subject to indemnification by Cardinal.

In June 2006, the Financial Accounting Standards Board (“FASB”) issued Interpretation No. 48, “Accounting for Uncertainty in Income Taxes”, (“FIN 48”) which is an interpretation of SFAS No.109, “Accounting for Income Taxes” (“FAS 109”). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with FAS 109. This standard also provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Effective July 1, 2007, the Company adopted the provisions of FIN 48 even though subsequent (“FASB”) guidance deferred the effective date for nonpublic enterprises until fiscal years beginning after December 15, 2007. As a result of adoption, the Company recognized no material adjustment in the liability for unrecognized income tax benefits. As of the adoption date, the Company had a total of \$5.2 million of unrecognized tax benefits. Of this amount, \$1.1 million represents the amount of unrecognized tax benefits that, if recognized, would favorably impact the effective income tax rate. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2007, the Company has approximately \$0.9 million of accrued interest related to uncertain tax positions.

9. EMPLOYEE RETIREMENT BENEFIT PLANS

Components of the Company’s net periodic benefit costs are as follows:

	Successor	Predecessor	Successor	Predecessor
	Three Months Ended December 31, 2007	Three Months Ended December 31, 2006	Six Months Ended December 31, 2007	Six Months Ended December 31, 2006
(in millions)				
Components of net periodic benefit cost:				
Service cost	\$ 0.6	\$ 0.5	\$ 1.1	\$ 0.9
Interest cost	3.6	3.0	7.1	5.9
Expected return on plan assets	(3.1)	(2.2)	(6.1)	(4.4)
Amortization ⁽¹⁾	-	0.8	-	1.7
Curtailement (Gain)/Loss	-	(0.1)	-	(0.1)
Net amount recognized	<u>\$ 1.1</u>	<u>\$ 2.0</u>	<u>\$ 2.1</u>	<u>\$ 4.0</u>

⁽¹⁾ Amount represents the amortization of unrecognized actuarial losses, as well as the amortization of the transition obligation and prior service costs.

10. RELATED PARTY TRANSACTIONS AND PREDECESSOR PARENT COMPANY TRANSACTIONS

Advisor Transaction and Management Fees - The Company pays an annual sponsor monitoring fee to Blackstone and the Investors for certain monitoring, advisory and consulting services to the Company. During the three and six months ended December 31, 2007, this management fee was approximately \$2.5 million and \$5.0 million, respectively and was expensed in selling, general and administrative expenses.

Cardinal Related Party - The Successor had entered into a transition services agreement with Cardinal in order to maintain certain critical general and administrative functions immediately after the Acquisition and continuing for various periods of time, none of which extend beyond September 2008, including certain human resources, IT support, tax and other services. During the three and six months ended December 31, 2007, the Company was charged \$3.3 million and \$6.6 million, respectively, for certain human resources, IT support, tax and other services. The expenses associated with the transition services agreement are included in selling, general and administrative expenses in the statement of operations.

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

As a result of the Acquisition, the Company will incur costs to separate certain shared service functions and systems from Cardinal. These costs are recorded as other special items as incurred in the statements of operations. As part of the Purchase Agreement, Cardinal will reimburse \$12.0 million of these separation expenses. During the three and six months ended December 31, 2007, the Company charged to expense \$3.8 million and \$6.8 million, respectively, and capitalized within property, plant and equipment of \$2.7 million in separation costs primarily related to professional fees and services. Through December 31, 2007, Cardinal has reimbursed \$10.3 million of separation expenses.

At December 31, 2007, the Company has recorded a receivable of \$11.2 million, primarily related to the remaining separation costs to be reimbursed of \$1.7 million and \$9.4 million of tax and other liabilities related to periods prior to the Acquisition that are the responsibility of Cardinal.

11. ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)

Accumulated other comprehensive income/(loss) consist of:

(in millions)	Currency Translation Adjustments	Unrealized Gains/(Losses) on Derivatives	Pension Liability Adjustments	Other Comprehensive Earnings/(Loss)
Balance at June 30, 2007	\$ 9.2	\$ -	\$ 1.8	\$ 11.0
Activity	33.6	(17.2)	-	16.4
Balance at December 31, 2007	<u>\$ 42.8</u>	<u>\$ (17.2)</u>	<u>\$ 1.8</u>	<u>\$ 27.4</u>

12. EQUITY-BASED COMPENSATION

The Company has an equity-based compensation plan outstanding as of December 31, 2007. In addition, the Predecessor was a party to the Cardinal equity-based compensation plan prior to the Acquisition. These plans are described in the Company's audited financial statements for the year ended June 30, 2007. The following table summarizes the impact of the equity-based compensation recorded in the Company's statement of operations as follows:

(in millions)	Successor Three Months Ended December 31, 2007	Predecessor Three Months Ended December 31, 2006	Successor Six Months Ended December 31, 2007	Predecessor Six Months Ended December 31, 2006
Stock compensation expense in selling, general and administrative	\$ 2.2	\$ 5.8	\$ 4.0	\$ 13.4
Income tax benefit on stock compensation expense	0.7	2.0	1.4	4.6

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

The activity of the Successor's equity based compensation program for the six months ended December 31, 2007 is presented below:

(in dollars)	<u>Time Based Awards</u>		<u>Performance Based Awards</u>		<u>Market Based Awards</u>	
	Number of Shares	Weighted Average Exercise Price	Number of Shares	Weighted Average Exercise Price	Number of Shares	Weighted Average Exercise Price
Balance at June 30, 2007	21,665	\$1,000	21,415	\$1,000	21,420	\$1,000
Granted at fair value	2,483	\$1,000	2,233	\$1,000	2,233	\$1,000
Exercised	-	-	-	-	-	-
Forfeited	(667)	\$1,000	(667)	\$1,000	(666)	\$1,000
Balance at December 31, 2007	<u>23,481</u>	<u>\$1,000</u>	<u>22,981</u>	<u>\$1,000</u>	<u>22,987</u>	<u>\$1,000</u>

BHP PTS Holdings, LLC, the ultimate parent of the Company, has granted to Aleksander Erdeljan, a Director of the Company, certain units, which are profits interest units which represent, in the aggregate, the right to receive up to less than 1% of the future appreciation of BHP PTS Holdings, LLC's equity above the enterprise value of BHP PTS Holdings, LLC on the date of issuance. The units vest in the same manner as the options vest under the 2007 Plan pursuant the terms of the Form Option Agreement.

13. COMMITMENT AND CONTINGENCIES

The Company, along with several pharmaceutical companies, is involved in nine product liability lawsuits relating to Amnesteem[®] (isotretinoin), a product manufactured by us. While it is not possible to determine with any degree of certainty the ultimate outcome of these legal proceedings including determination of liability, the Company believes that it has meritorious defenses with respect to the claims asserted against it and intends to vigorously defend its position.

The Company also becomes involved from time-to-time in disputes or litigation incidental to its business, including without limitation, inclusion of certain of its subsidiaries as a potentially responsible party for environmental clean-up costs and disputes involving the loss of a customer's active pharmaceutical ingredient incidental to the Company's manufacturing services. The Company intends to vigorously defend itself against such disputes and litigation and does not currently believe that the outcome of any such disputes or litigation will have a material adverse effect on the Company's financial statements.

14. SEGMENT INFORMATION

The Company conducts its business, within the following three segments: Oral Technologies, Sterile Technologies, and Packaging Services. The Company evaluates the performance of its segments based on segment net earnings before interest income/expense, provision (benefit) for income taxes and depreciation and amortization ("EBITDA"). The Company's presentation of EBITDA may not be comparable to similarly-titled measures used by other companies.

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

The following tables include net revenue and EBITDA during the three and six months ended December 31, 2007 and three and six months ended December 31, 2006.

(in millions)	<u>Successor</u> <u>Three Months</u> <u>Ended</u> <u>December 31,</u> <u>2007</u>	<u>Predecessor</u> <u>Three Months</u> <u>Ended</u> <u>December 31,</u> <u>2006</u>	<u>Successor</u> <u>Six Months</u> <u>Ended</u> <u>December 31,</u> <u>2007</u>	<u>Predecessor</u> <u>Six Months</u> <u>Ended</u> <u>December 31,</u> <u>2006</u>
Oral Technologies				
Net revenue	\$ 256.9	\$ 230.6	\$ 492.1	\$ 447.0
Segment EBITDA	50.5	55.5	99.9	97.6
Sterile Technologies				
Net revenue	74.1	60.7	144.6	116.6
Segment EBITDA	4.6	0.4	10.7	(4.7)
Packaging Services				
Net revenue	143.7	134.7	285.4	272.5
Segment EBITDA	19.7	18.1	40.5	35.1
Inter-segment revenue elimination	(10.7)	(9.5)	(20.1)	(21.1)
Unallocated Costs⁽¹⁾	(30.0)	(24.9)	(48.5)	(47.5)
Combined Total				
Net revenue	464.0	416.5	902.0	815.0
EBITDA from continuing operations	\$ 44.8	\$ 49.1	\$ 102.6	\$ 80.5

⁽¹⁾ Unallocated Costs include special items, equity-based compensation, impairment charges, certain other Corporate directed costs, and other costs that are not allocated to the segments as follows:

(in millions)	<u>Successor</u> <u>Three Months</u> <u>Ended December 31,</u> <u>2007</u>	<u>Predecessor</u> <u>Three Months</u> <u>Ended December</u> <u>31, 2006</u>	<u>Successor</u> <u>Six Months</u> <u>Ended December</u> <u>31, 2007</u>	<u>Predecessor</u> <u>Six Months</u> <u>Ended December</u> <u>31, 2006</u>
Impairment charges and gain/(loss) on sale of assets	\$ -	\$ (0.9)	\$ (0.4)	\$ (3.1)
Equity compensation	(2.2)	(5.8)	(4.0)	(13.4)
Restructuring and other special items	(9.0)	(5.9)	(13.3)	(8.0)
Sponsor advisory fee	(2.5)	-	(5.0)	-
Minority interest, net	(0.6)	(2.0)	(0.3)	(2.2)
Other, net	(10.6)	0.2	(19.8)	-
Non-allocated corporate costs, net	(5.1)	(10.5)	(5.7)	(20.8)
Total unallocated costs	<u>\$ (30.0)</u>	<u>\$ (24.9)</u>	<u>\$ (48.5)</u>	<u>\$ (47.5)</u>

Provided below is a reconciliation of EBITDA to earnings/(loss) from continuing operations:

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

(in millions)	Successor	Predecessor	Successor	Predecessor
	Three Months Ended December 31, 2007	Three Months Ended December 31, 2006	Six Months Ended December 31, 2007	Six Months Ended December 31, 2006
EBITDA	\$ 44.8	\$ 49.1	\$ 102.6	\$ 80.5
Depreciation and amortization	(41.6)	(24.5)	(82.3)	(48.3)
Interest expense, net	(52.0)	(1.0)	(101.3)	(2.6)
Benefit for income taxes	19.6	4.1	44.0	3.8
Earnings/(loss) from continuing operations	\$ (29.2)	\$ 27.7	\$ (37.0)	\$ 33.4

The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the financial statements:

Assets

(in millions)

	December 31, 2007	June, 30 2007
Oral Technologies	\$ 2,137.1	\$ 2,173.7
Sterile Technologies	997.0	918.3
Packaging Services	877.8	861.1
Corporate and eliminations	(253.6)	(173.1)
Assets held for sale	73.9	82.3
Total assets	\$ 3,832.2	\$ 3,862.3

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

15. SUPPLEMENTAL BALANCE SHEET INFORMATION

Supplementary balance sheet information at December 31, 2007 and June 30, 2007, are detailed in the following tables, and reflect the impact of the evaluation of the fair values of the real and personal property, inventory and certain identifiable intangible assets in connection with the purchase price allocation related to the Acquisition, as follows:

Inventories

Work-in-process and finished goods inventories include raw materials, labor and overhead. Inventories consisted of the following:

(in millions)	<u>December 31,</u> <u>2007</u>	<u>June 30,</u> <u>2007</u>
Raw materials and supplies	\$ 127.3	\$ 116.9
Work-in-process	32.1	34.3
Finished goods	65.4	70.3
Total inventory, gross	224.8	221.5
Inventory reserves	(6.4)	(2.6)
Total inventory, net	<u>\$ 218.4</u>	<u>\$ 218.9</u>

Property and equipment

Property and equipment consist of the following:

(in millions)	<u>December 31,</u> <u>2007</u>	<u>June 30,</u> <u>2007</u>
Land, buildings and improvements	\$ 467.5	\$ 431.5
Machinery and equipment	641.8	566.1
Furniture and fixtures	11.9	11.1
Construction in progress	42.9	76.0
Property and equipment, at cost	1,164.1	1,084.7
Accumulated depreciation	(113.2)	(28.6)
Property and equipment, net	<u>\$ 1,050.9</u>	<u>\$ 1,056.1</u>

16. GUARANTOR AND NON GUARANTOR FINANCIAL STATEMENTS

All obligations under the senior secured credit agreement, the senior toggle notes and the senior subordinated notes are unconditionally guaranteed by each of the Company's existing U.S. wholly owned subsidiaries, other than the Company's Puerto Rico subsidiaries, subject to certain exceptions.

The following condensed financial information presents the Company's Consolidating Balance Sheet as of December 31, 2007 and as of June 30, 2007 and the Consolidating Statement of Operations and Statement of Cash Flows for the three and six months ended December 31, 2007 and the Predecessor's Combining Statements of Operations and Cash Flows for the three and six months ended December 31, 2006 for: (a) Catalent Pharma Solutions, Inc. ("Issuer and/or Parent"); (b) the guarantor subsidiaries; (c) the non guarantor subsidiaries and (d) elimination and adjustment entries necessary to combine the Issuer/Parent with the guarantor and non guarantor subsidiaries on a Consolidated and Combined basis, respectively.

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

Catalent Pharma Solutions, Inc. and Subsidiaries
Consolidating Statements of Operations
For the three months ended December 31, 2007
(Successor)

	<u>Issuer</u>	<u>Guarantor Subsidiaries</u>	<u>Non Guarantors Subsidiaries</u>	<u>Eliminations</u>	<u>Successor Combined</u>
Net revenue	\$ -	\$ 176.4	\$ 293.6	\$ (6.0)	\$ 464.0
Cost of products sold	-	126.4	236.0	(6.0)	356.4
Gross margin	-	50.0	57.6	-	107.6
Selling, general and administrative expenses	-	45.0	39.2	-	84.2
Restructuring and other special items	-	9.0	-	-	9.0
Operating earnings/(loss)	-	(4.0)	18.4	-	14.4
Interest expense, net	49.4	(0.3)	2.9	-	52.0
Other, net	(19.2)	(3.1)	12.6	20.3	10.6
Earnings/(loss) from continuing operations before income taxes and minority interest	(30.2)	(0.6)	2.9	(20.3)	(48.2)
Income tax (benefit)/expense	-	(19.2)	(0.4)	-	(19.6)
Minority interest, net of tax benefit of \$0.2 million	-	-	0.6	-	0.6
(Loss)/earnings from continuing operations	(30.2)	18.6	2.7	(20.3)	(29.2)
Loss from discontinued operations, net of tax benefit of \$0.2 million	-	(0.9)	(0.1)	-	(1.0)
Net earnings/ (loss)	<u>\$ (30.2)</u>	<u>\$ 17.7</u>	<u>\$ 2.6</u>	<u>\$ (20.3)</u>	<u>\$ (30.2)</u>

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

Catalent Pharma Solutions, Inc. and Subsidiaries
Consolidating Statements of Operations
For the six months ended December 31, 2007
(Successor)

	<u>Issuer</u>	<u>Guarantor Subsidiaries</u>	<u>Non Guarantors Subsidiaries</u>	<u>Eliminations</u>	<u>Successor Combined</u>
Net revenue	\$ -	\$ 343.7	\$ 568.9	\$ (10.6)	\$ 902.0
Cost of products sold	-	247.8	452.2	(10.6)	689.4
Gross margin	-	95.9	116.7	-	212.6
Selling, general and administrative expenses	-	86.2	72.3	-	158.5
Impairment charges and (gain)/loss on sale of asset	-	0.2	0.2	-	0.4
Restructuring and other special items	-	12.5	0.8	-	13.3
Operating earnings/(loss)	-	(3.0)	43.4	-	40.4
Interest expense, net	98.2	(0.2)	3.3	-	101.3
Other, net	(56.7)	(2.3)	22.9	55.9	19.8
Earnings/(loss) from continuing operations before income taxes and minority interest	(41.5)	(0.5)	17.2	(55.9)	(80.7)
Income tax (benefit)/expense	-	(39.5)	(4.5)	-	(44.0)
Minority interest, net of tax benefit of \$0.1 million	-	-	0.3	-	0.3
(Loss)/earnings from continuing operations	(41.5)	39.0	21.4	(55.9)	(37.0)
Loss from discontinued operations, net of tax expense of \$0.5 million	-	(2.4)	(2.1)	-	(4.5)
Net earnings/ (loss)	<u>\$ (41.5)</u>	<u>\$ 36.6</u>	<u>\$ 19.3</u>	<u>\$ (55.9)</u>	<u>\$ (41.5)</u>

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

Catalent Pharma Solutions, Inc. and Subsidiaries
Combining Statements of Operations
For the three months ended December 31, 2006
(Predecessor)

	<u>Issuer</u>	<u>Guarantor Subsidiaries</u>	<u>Non Guarantors Subsidiaries</u>	<u>Eliminations</u>	<u>Predecessor Combined</u>
Net revenue	\$ -	\$ 172.5	\$ 246.9	\$ (2.9)	\$ 416.5
Cost of products sold	-	126.8	185.6	(2.9)	309.5
Gross margin	-	45.7	61.3	-	107.0
Selling, general and administrative expenses	-	46.6	27.2	-	73.8
Impairment charges and (gain)/loss on sale of asset	-	0.6	0.3	-	0.9
Restructuring and other special items	-	5.9	-	-	5.9
Operating earnings/(loss)	-	(7.4)	33.8	-	26.4
Interest expense, net	(0.6)	(3.3)	4.9	-	1.0
Other, net	(17.3)	(4.2)	3.3	18.0	(0.2)
Earnings/(loss) from continuing operations before income taxes and minority interest	17.9	0.1	25.6	(18.0)	25.6
Income tax (benefit)/expense	-	(12.1)	8.0	-	(4.1)
Minority interest, net of tax benefit \$1.6 million	-	-	2.0	-	2.0
Earnings/(loss) from continuing operations	17.9	12.2	15.6	(18.0)	27.7
Loss from discontinued operations, net of tax expense \$3.6 million	-	(7.8)	(1.4)	-	(9.2)
Net earnings/(loss)	<u>\$ 17.9</u>	<u>\$ 4.4</u>	<u>\$ 14.2</u>	<u>\$ (18.0)</u>	<u>\$ 18.5</u>

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

Catalent Pharma Solutions, Inc. and Subsidiaries
Combining Statements of Operations
For the six months ended December 31, 2006
(Predecessor)

	<u>Issuer</u>	<u>Guarantor Subsidiaries</u>	<u>Non Guarantors Subsidiaries</u>	<u>Eliminations</u>	<u>Predecessor Combined</u>
Net revenue	\$ -	\$ 341.7	\$ 482.2	\$ (8.9)	\$ 815.0
Cost of products sold	-	257.5	372.8	(8.9)	621.4
				-	
Gross margin	-	84.2	109.4		193.6
Selling, general and administrative expenses	-	99.6	48.5	-	148.1
Impairment charges and (gain)/loss on sale of asset	-	0.8	2.3	-	3.1
Restructuring and other special items	-	8.0	-	-	8.0
Operating earnings/(loss)	-	(24.2)	58.6	-	34.4
Interest expense, net	(1.2)	(1.8)	5.6	-	2.6
Other, net	(17.7)	(4.7)	4.0	18.4	-
Earnings/(loss) from continuing operations before income taxes and minority interest	18.9	(17.7)	49.0	(18.4)	31.8
Income tax (benefit)/expense	-	(17.2)	13.4	-	(3.8)
Minority interest, net of tax benefit \$1.8 million	-	-	2.2	-	2.2
Earnings/(loss) from continuing operations	18.9	(0.5)	33.4	(18.4)	33.4
Loss from discontinued operations, net of tax expense \$1.1 million	-	(11.8)	(2.0)	-	(13.8)
Net earnings/(loss)	<u>\$ 18.9</u>	<u>\$ (12.3)</u>	<u>\$ 31.4</u>	<u>\$ (18.4)</u>	<u>\$ 19.6</u>

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

Catalent Pharma Solutions, Inc. and Subsidiaries
Consolidating Balance Sheet
December 31, 2007
(Successor)

	<u>Issuer</u>	<u>Guarantor Subsidiaries</u>	<u>Non Guarantors Subsidiaries</u>	<u>Eliminations</u>	<u>Successor Combined</u>
Assets					
Current Assets:					
Cash and equivalents	\$ -	\$ 5.3	\$ 54.2	\$ -	\$ 59.5
Trade receivables, net	-	104.9	189.5	-	294.4
Intercompany receivables	-	57.1	-	(57.1)	-
Receivables due from Cardinal Health, Inc and affiliates	11.2	-	-	-	11.2
Inventories, net	-	58.5	159.9	-	218.4
Prepaid expenses and other	-	21.7	48.4	-	70.1
Assets held for sale	-	34.3	39.6	-	73.9
Total current assets	<u>11.2</u>	<u>281.8</u>	<u>491.6</u>	<u>(57.1)</u>	<u>727.5</u>
Property and equipment, net	-	509.3	541.6	-	1,050.9
Goodwill	-	523.2	944.5	-	1,467.7
Other intangibles, net	-	230.2	295.9	-	526.1
Investment in subsidiaries	3,128.4	-	-	(3,128.4)	-
Intercompany long-term receivable	37.8	13.6	-	(51.4)	-
Other	51.8	5.4	2.8	-	60.0
Total assets	<u>\$ 3,229.2</u>	<u>\$ 1,563.5</u>	<u>\$ 2,276.4</u>	<u>\$(3,236.9)</u>	<u>\$ 3,832.2</u>
Current Liabilities					
Current portion of long-term obligations and other short-term borrowings	\$ 44.5	\$ 3.6	\$ 0.6	\$ -	\$ 48.7
Accounts payable	-	48.4	66.8	-	115.2
Intercompany accounts payable	33.0	-	24.1	(57.1)	-
Other accrued liabilities	35.5	66.6	82.7	-	184.8
Liabilities held for sale	-	8.8	17.6	-	26.4
Total current liabilities	<u>113.0</u>	<u>127.4</u>	<u>191.8</u>	<u>(57.1)</u>	<u>375.1</u>
Long-term obligations, less current portion	2,318.7	5.4	-	-	2,324.1
Intercompany long-term debt	-	-	51.4	(51.4)	-
Other liabilities	-	36.2	193.2	-	229.4
Commitment and Contingencies	-	-	-	-	-
Common stock \$0.1 par value; 1,000 shares authorized, 100 shares issued	-	-	-	-	-
Additional paid in capital	1,068.0	-	-	-	1,068.0
Parent company equity	-	1,389.2	1,739.2	(3,128.4)	-
Accumulated deficit	(191.8)	-	-	-	(191.8)
Accumulated other comprehensive income/(loss)	(78.7)	5.3	100.8	-	27.4
Total Shareholder's and Parent company equity	<u>797.5</u>	<u>1,394.5</u>	<u>1,840.0</u>	<u>(3,128.4)</u>	<u>903.6</u>
Total liabilities and parent company equity	<u>\$ 3,229.2</u>	<u>\$ 1,563.5</u>	<u>\$ 2,276.4</u>	<u>\$(3,236.9)</u>	<u>\$ 3,832.2</u>

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

Catalent Pharma Solutions, Inc. and Subsidiaries
Consolidating Balance Sheet
June 30, 2007
(Successor)

	Issuer	Guarantor Subsidiaries	Non Guarantors Subsidiaries	Eliminations	Successor Combined
Assets					
Current Assets:					
Cash and equivalents	\$ -	\$ 15.3	\$ 67.4	\$ -	\$ 82.7
Trade receivables, net	-	119.0	191.3	-	310.3
Intercompany receivables	14.9	6.3	-	(21.2)	-
Receivables due from Cardinal Health, Inc and affiliates	13.6	0.1	-	-	13.7
Inventories, net	-	60.0	158.9	-	218.9
Prepaid expenses and other	0.1	21.6	46.6	-	68.3
Assets held for sale	-	39.7	42.6	-	82.3
Total current assets	<u>28.6</u>	<u>262.0</u>	<u>506.8</u>	<u>(21.2)</u>	<u>776.2</u>
Property and equipment, net	-	525.3	530.8	-	1,056.1
Goodwill	-	513.8	907.9	-	1,421.7
Other intangibles, net	-	239.9	306.4	-	546.3
Investment in subsidiaries	3,072.4	-	-	(3,072.4)	-
Intercompany long-term receivable	58.5	13.2	-	(71.7)	-
Other	54.7	5.5	1.8	-	62.0
Total assets	<u>\$3,214.2</u>	<u>\$ 1,559.7</u>	<u>\$ 2,253.7</u>	<u>\$ (3,165.3)</u>	<u>\$ 3,862.3</u>
Liabilities and Shareholder's and Parent Company Equity					
Current Liabilities					
Current portion of long-term obligations and other short-term borrowings	\$ 28.1	\$ 7.4	\$ 0.9	\$ -	\$ 36.4
Accounts payable	-	29.1	85.5	-	114.6
Intercompany accounts payable	-	-	21.2	(21.2)	-
Other accrued liabilities	19.3	60.8	94.4	-	174.5
Liabilities held for sale	-	8.9	27.2	-	36.1
Total current liabilities	<u>47.4</u>	<u>106.2</u>	<u>229.2</u>	<u>(21.2)</u>	<u>361.6</u>
Long-term obligations, less current portion	2,269.4	6.2	-	-	2,275.6
Intercompany long-term debt	-	-	71.7	(71.7)	-
Other liabilities	-	92.5	222.0	-	314.5
Commitment and Contingencies	-	-	-	-	-
Shareholder's and Parent Company Equity:					
Common stock \$0.1 par value; 1,000 shares authorized, 100 shares issued	-	-	-	-	-
Additional paid in capital	1,049.9	-	-	-	1,049.9
Parent company equity	-	1,352.6	1,719.8	(3,072.4)	-
Accumulated deficit	(150.3)	-	-	-	(150.3)
Accumulated other comprehensive income/(loss)	(2.2)	2.2	11.0	-	11.0
Total Shareholder's and Parent company equity	<u>897.4</u>	<u>1,354.8</u>	<u>1,730.8</u>	<u>(3,072.4)</u>	<u>910.6</u>
Total liabilities and parent equity	<u>\$3,214.2</u>	<u>\$ 1,559.7</u>	<u>\$ 2,253.7</u>	<u>\$ (3,165.3)</u>	<u>\$ 3,862.3</u>

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

Catalent Pharma Solutions, Inc. and Subsidiaries
Consolidating Statements of Cash Flows
For the six months ended December 31, 2007
(Successor)

	Issuer	Guarantor Subsidiaries	Non Guarantors Subsidiaries	Eliminations	Successor Combined
Cash Flows From Operating Activities:					
Net (loss)/ earnings	\$ (41.5)	\$ 36.6	\$ 19.3	\$ (55.9)	\$ (41.5)
Loss from discontinued operations	-	(2.4)	(2.1)	-	(4.5)
(Loss)/earnings from continuing operations	(41.5)	39.0	21.4	(55.9)	(37.0)
Adjustments to reconcile (loss)/earnings from continued operations to net cash from operations:					
Depreciation and amortization	-	37.7	44.6	-	82.3
Amortization of debt financing costs	3.7	-	-	-	3.7
Income from subsidiaries	(55.9)	-	-	55.9	-
Minority interest	-	-	0.3	-	0.3
Asset impairments and (gain)/loss on sale of assets	-	-	0.4	-	0.4
Equity compensation	-	4.0	-	-	4.0
Benefit for deferred income taxes	-	(73.8)	13.6	-	(60.2)
Non-cash restructuring and other special items	-	0.9	-	-	0.9
Change in operating assets and liabilities net of acquisitions:					
(Increase) decrease in trade receivables		14.1	1.7		15.8
(Increase) decrease in inventories	-	1.5	(0.9)	-	0.6
Increase) decrease in inventories	-	19.3	(20.6)	-	(1.3)
Change in accrued liabilities and other operating	0.7	22.4	(67.7)	-	(44.6)
Net cash provided by/(used in) operating activities from continuing operations	(93.0)	65.1	(7.2)	-	(35.1)
Net cash provided by/(used in) operating activities from continuing operations	-	(6.0)	5.2	-	(0.8)
Net cash provided by/(used in) operating activities	(93.0)	59.1	(2.0)	-	(35.9)
Cash Flows From Investing Activities:					
Proceeds from sale of assets	-	0.3	-	-	0.3
Additions to property and equipment	-	(12.4)	(25.1)	-	(37.5)
Net cash used in investing activities from continuing operations	-	(12.1)	(25.1)	-	(37.2)
Net cash used in investing activities from discontinued operations	-	(0.3)	(0.8)	-	(1.1)
Net cash used in investing activities	-	(12.4)	(25.9)	-	(38.3)
Cash Flows From Financing Activities:					
Intercompany	72.5	(55.2)	(17.3)	-	-
Net change to debt obligations	8.9	(4.6)	(0.9)	-	3.4
Equity contribution	14.1	-	-	-	14.1
Net cash provided by/(used in) financing activities from continuing operations	95.5	(59.8)	(18.2)	-	17.5
Net cash provided by/(used in) financing activities from discontinued operations	-	-	-	-	-
Net cash provided by/(used in) financing activities	95.5	(59.8)	(18.2)	-	17.5
Effect of foreign currency	(2.5)	3.1	32.9	-	33.5
Net Decrease in Cash and Equivalents	-	(10.0)	(13.2)	-	(23.2)
Cash and Equivalents at Beginning of Year	-	15.3	67.4	-	82.7
Cash and Equivalents at end of Year	\$ -	\$ 5.3	\$ 54.2	-	59.5

Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor
Notes to Unaudited Consolidated and Combined Condensed Financial Statements
(in millions, except shares)

Catalent Pharma Solutions, Inc. and Subsidiaries
Consolidating Statements of Cash Flows
For the six months ended December 31, 2006
(Predecessor)

	Issuer	Guarantor Subsidiaries	Non Guarantors Subsidiaries	Eliminations	Predecessor Combined
Cash Flows From Operating Activities:					
Net earnings/(loss)	\$ 18.9	\$ (12.3)	\$ 31.4	\$ (18.4)	\$ 19.6
Loss from discontinued operations	-	(11.8)	(2.0)	-	(13.8)
Earnings (loss) from continuing operations	18.9	(0.5)	33.4	(18.4)	33.4
Adjustments to reconcile earnings/(loss) from continued operations to net cash from operations:					
Depreciation and amortization	-	22.5	25.8	-	48.3
Income from subsidiaries	(18.4)	-	-	18.4	-
Minority interest	-	-	2.2	-	2.2
Asset impairments and (gain)/loss on sale of assets	-	0.8	2.3	-	3.1
Non-cash restructuring and other special items	-	0.5	-	-	0.5
Equity-based compensation	-	13.4	-	-	13.4
Change in operating assets and liabilities net of acquisitions:					
Decrease in trade receivables	-	7.7	13.6	-	21.3
(Increase)/decrease in inventories	-	14.0	(15.9)	-	(1.9)
Decrease in accounts payable	-	(4.1)	(1.5)	-	(5.6)
Change in accrued liabilities and other operating	(0.7)	(53.2)	21.7	-	(32.1)
Net cash provided by/(used in) operating activities from continuing operations	(0.2)	1.1	81.6	-	82.5
Net cash provided by/(used in) operating activities from discontinued operations	-	(4.0)	3.5	-	(0.5)
Net cash provided by/(used in) operating activities	(0.2)	(2.9)	85.1	-	82.0
Cash Flows From Investing Activities:					
Proceeds from sale of assets	-	10.7	1.0	-	11.7
Additions to property and equipment	-	(19.9)	(13.6)	-	(33.5)
Net cash used in investing activities from continuing operations	-	(9.2)	(12.6)	-	(21.8)
Net cash used in investing activities from discontinued operations	-	(0.2)	(1.6)	-	(1.8)
Net cash used in investing activities	-	(9.4)	(14.2)	-	(23.6)
Cash Flows From Financing Activities:					
Intercompany	6.7	19.0	(25.7)	-	-
Net change to debt obligations	-	(0.9)	(1.0)	-	(1.9)
Net investment	(6.5)	(2.3)	(19.6)	-	(28.4)
Net cash provided by/(used in) financing activities from continuing operations	0.2	15.8	(46.3)	-	(30.3)
Net cash provided by/(used in) financing activities from discontinued operations	-	-	-	-	-
Net cash provided by/(used in) financing activities	0.2	15.8	(46.3)	-	(30.3)
Effect of foreign currency	-	(0.3)	5.0	-	4.7
Net Increase in Cash and Equivalents	-	3.2	29.6	-	32.8
Cash and Equivalents at Beginning of Year	-	(3.4)	137.0	-	133.6
Cash and Equivalents at End of Year	\$ -	\$ (0.2)	\$ 166.6	\$ -	\$ 166.4

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our Unaudited Consolidated and Combined Condensed Financial Statements and accompanying Notes thereto included elsewhere herein and with our Fiscal 2007 Consolidated and Combined Financial Statements. Unless otherwise noted, all dollar amounts are in millions.

The Company

On April 10, 2007, an entity controlled by affiliates of Blackstone acquired from Cardinal Health, Inc. ("Cardinal") certain assets and liabilities of the Pharmaceutical Technologies and Services ("PTS") business segment of Cardinal (excluding certain businesses described in Note 1 to the Company's Unaudited Condensed Financial Statements herein) (hereinafter collectively "Catalent Pharma Solutions, Inc.", "Catalent", the "Company", or the "Successor"), pursuant to a Purchase and Sale Agreement dated as of January 25, 2007 (the "Acquisition"). The Acquisition aggregate purchase price of approximately \$3.3 billion was funded with approximately \$1.0 billion in cash equity contributions from a Blackstone affiliate, \$1.4 billion in proceeds from the issuance of term loans under a new senior credit facility, \$565.0 million in proceeds from the issuance of senior toggle notes, and \$300.3 million in proceeds from the issuance of senior subordinated notes. In addition, costs associated with issuing these long-term debt obligations approximated \$56.3 million and are capitalized on the Company's balance sheet and are being amortized to interest expense over the respective terms of the debt instruments.

Historical Ownership by Cardinal

We historically operated as a portion of the PTS business segment of Cardinal and not as a stand-alone company (the "Predecessor"). The combined financial statements for all periods prior to April 10, 2007 included herein reflect the operations that were acquired as part of the Acquisition and have been derived from the historical consolidated financial statements of Cardinal using the historical results of our operations and the historical basis of our assets and liabilities.

As the Predecessor, we were allocated general corporate overhead expenses from Cardinal for corporate-related functions and corporate overhead expense. We believe the assumptions and methodologies underlying the allocations from Cardinal are reasonable. However, such expenses are not indicative of, nor is it practical or meaningful for us to estimate for all historical periods presented, the actual level of expenses that would have been incurred had we been operating as a separate, stand-alone public or private company during such periods. See Notes 1 and 11 of our June 30, 2007 Consolidated and Combined Financial Statements for further discussion of amounts charged by Cardinal.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States ("US GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. Some of the more significant estimates used include those used in accounting for the Acquisition under the purchase method of accounting, and prior to the acquisition, in allocating certain costs to the Predecessor in order to present the Predecessor's operating results on a stand alone basis. The Company believes that the understanding of certain key accounting policies and estimates are essential in achieving more insight into the Company's operating results and financial condition. These key accounting policies include, but are not limited to allowance for doubtful accounts, the valuation of long-lived and intangible assets, equity-based compensation, income taxes, and currency risk management.

There were no significant changes to these policies or in the underlying accounting assumptions and estimates used in the critical accounting policies from those disclosed in the Company's Fiscal 2007 Consolidated and Combined Financial Statements.

Recent Financial Accounting Standards

In February 2006, the FASB issued SFAS No. 155, "Accounting for Certain Hybrid Financial Instruments," an amendment of SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities" and SFAS No. 140, "Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities." This Statement permits fair value remeasurement for any hybrid financial instrument that contains an embedded derivative that would otherwise be required to be bifurcated from its host contract. The election to measure a hybrid financial instrument at fair value, in its entirety, is irrevocable and all changes in fair value are to be recognized in earnings. This Statement also clarifies and amends certain provisions of SFAS No. 133 and SFAS No. 140. This Statement is effective for all financial instruments acquired, issued or subject to a remeasurement event occurring in fiscal years beginning after September 15, 2006. Early adoption is permitted, provided the Company has not yet issued financial statements, including financial statements for any interim period, for that fiscal year. The adoption of this Statement did not have a material impact on the Company's financial position or results of operations.

In July 2006, the FASB issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes." This Interpretation prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. While this Interpretation is generally effective for fiscal years beginning after December 15, 2006, the FASB has deferred this effective date for nonpublic enterprises to fiscal years beginning after December 15, 2007. However the Company has adopted the provisions of FIN 48 effective July 1, 2007. The cumulative effects, if any, of applying this Interpretation will be recorded as an adjustment to accumulated deficit as of the beginning of the period of adoption. The adoption of this Interpretation did not have a material impact on the Company's financial position or results of operations.

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements." This Statement defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. This Statement is effective for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company is in the process of determining the impact of adopting this Statement.

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities." SFAS No. 159 permits an entity, on a contract-by-contract basis, to make an irrevocable election to account for certain types of financial instruments and warranty and insurance contracts at fair value, rather than historical cost, with changes in the fair value, whether realized or unrealized, recognized in earnings. SFAS No. 159 is effective for the Company in the first quarter of fiscal 2009. The Company is in the process of determining the impact of adopting this Statement.

In June 2007, the Emerging Issues Task Force reached a consensus on Issue No. 07-3, *Accounting for Nonrefundable Advance Payments for Goods or Services Received for Use in Future Research and Development Activities*. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. Such amounts should be recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided. This Issue is effective for financial statements issued for fiscal years beginning after December 15, 2007, and earlier application is not permitted. This consensus is to be applied prospectively for new contracts entered into on or after the effective date. The Company is evaluating the potential impact of this consensus and does not expect it to have a material effect on its consolidated financial statements.

In December 2007, the FASB issued SFAS No. 141 (revised 2007), "Business Combinations." SFAS No. 141R establishes principles and requirements for how the acquirer in a business combination recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquiree at the acquisition date fair value. SFAS No. 141R determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. SFAS No. 141R applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. Early adoption is not permitted. The Company is in the process of determining the impact of adopting this Statement.

In December 2007, the Securities and Exchange Commission ("SEC") issued Staff Accounting Bulletin No. 110 ("SAB 110"). SAB 110 amends and replaces Question 6 of Section D.2 of Topic 14, *Share-Based Payment*. SAB 110 expresses the

views of the staff regarding the use of the “simplified” method in developing an estimate of expected term of “plain vanilla” share options in accordance with FASB Statement No. 123(R), *Share Based Payment*. The use of the “simplified” method was scheduled to expire on December 31, 2007. SAB 110 extends the use of the “simplified” method for “plain vanilla” awards in certain situations. The Company currently uses the “simplified” method to estimate the expected term for share option grants as it does not have enough historical experience to provide a reasonable estimate due to the limited period the Company’s equity shares have been publicly traded. The Company will continue to use the “simplified” method until it has enough historical experience to provide a reasonable estimate of expected term in accordance with SAB 110. SAB 110 is effective for options granted after December 31, 2007.

On December 4, 2007, the FASB issued SFAS No. 160, *Noncontrolling Interests in Consolidated Financial Statements* (SFAS 160). SFAS 160 is an amendment of Accounting Research Bulletin (ARB) No. 51 and was issued to improve the relevance, comparability, and transparency of the financial information that a reporting entity provides in its consolidated financial statements. This Statement applies to all entities that prepare consolidated financial statements, except not-for-profit organizations, but will affect only those entities that have an outstanding noncontrolling interest in one or more subsidiaries. SFAS 160 clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements and that a parent company must recognize a gain or loss in net income when a subsidiary is deconsolidated. SFAS 160 is effective for fiscal years beginning after December 15, 2008 and early adoption is prohibited. The Company is currently evaluating the potential impact on its statement of financial position and results of operations.

Results of Operations

Management measures operating performance from operating earnings to net earnings before interest expense, provision (benefit) for income taxes and depreciation and amortization (“EBITDA”). The term EBITDA is not defined under (“U.S. GAAP”). EBITDA is not a measure of operating income, operating performance or liquidity presented in accordance with U.S. GAAP and is subject to important limitations.

We believe that the presentation of EBITDA enhances an investor’s understanding of our financial performance. We believe that EBITDA is a useful financial metric to assess our operating performance from period to period by excluding certain items that we believe are not representative of our core business. We also believe EBITDA is useful to assess our ability to generate cash from operations sufficient to pay taxes, to service debt and to undertake capital expenditures. We use EBITDA for business planning purposes. In addition, given the significant investments that we have made in the past in property, plant and equipment, depreciation and amortization expenses represent a meaningful portion of our cost structure. We believe that EBITDA will provide investors with a useful tool for assessing the comparability between periods of our ability to generate cash from operations sufficient to pay taxes, to service debt and to undertake capital expenditures because it eliminates depreciation and amortization expense.

SEC rules regulate the use in filings with the SEC of “non-GAAP financial measures,” such as EBITDA and segment EBITDA that are derived on the basis of methodologies other than in accordance U.S. GAAP. We present certain non-GAAP measures in order to provide supplemental information that we consider relevant for the readers of the financial statements, and such information is not meant to replace or supersede U.S. GAAP measures. The non-U.S. GAAP measures may not be the same as similarly titled measures used by other companies.

The financial statements present our results for the three and six month periods ended December 31, 2007 and on a “predecessor basis” for the three and six month periods ended December 31, 2006 (reflecting Predecessor ownership by Cardinal). The Successor was created as a result of the Acquisition of the Predecessor’s businesses from Cardinal on April 10, 2007. See Notes 1 and 2 of the Consolidated and Combined Condensed Financial Statements for further discussion of the Acquisition.

For purpose of management’s discussion and analysis of the results of operations, we have compared the results of the Successor for the three and six month periods in fiscal 2008 with those of the Predecessor in the three and six month periods in fiscal 2007. The results of the two periods are not necessarily comparable due to the change in basis of accounting resulting from the Acquisition and the change in the capital structure, which primarily impact depreciation, amortization and interest expense. The captions included within our statements of operations that are materially impacted by the change in basis of accounting include depreciation and amortization expense, gross margin, selling, general and administrative expenses and

interest expense. We have disclosed the impact of the change in basis of accounting for each of these captions in the following discussion of our results of operations.

In accordance with SFAS No. 141 at the date of Acquisition, the acquired assets and liabilities were recorded at their estimated fair values. The following table summarizes the preliminary allocation of fair values of the Company's assets acquired and liabilities assumed at the date of acquisition.

<i>(in millions)</i>	<u>April 10, 2007</u>
Current assets	\$ 707.0
Property and equipment	1,055.2
Intangible assets	556.3
In-process research and development	112.4
Other assets	64.4
Total assets	<u>2,495.3</u>
Current liabilities	(266.2)
Long term debt	(2,271.4)
Non current liabilities	(135.9)
Deferred taxes	(193.3)
Total liabilities	<u>(2,866.8)</u>
Equity contributions	<u>(1,048.9)</u>
Excess purchase price attributable to goodwill	<u>\$ 1,420.4</u>

The following table summarizes the preliminary allocation of the Acquisition purchase price:

<i>(in millions)</i>	<u>April 10, 2007</u>
Purchase price allocation:	
Purchase price	\$ 3,216.5
Transaction fees and expenses	69.1
Total purchase price	<u>3,285.6</u>
Less:	
Net tangible assets acquired	1,292.7
Fair value adjustment to inventory (a)	29.4
Fair value adjustment to property and equipment (b)	16.8
Other intangible assets acquired	556.3
In-process research and development (c)	112.4
Net assets held for sale	50.9
Deferred income tax liabilities	(193.3)
Excess purchase price attributable to goodwill	<u>\$ 1,420.4</u>

- (a) Resulted in an increase in value of inventory and a corresponding charge to cost of products sold related to higher costs of inventory sold during the period April 10, 2007 to June 30, 2007;
- (b) Resulted in an increase in value of property, plant and equipment as well as intangible assets and a corresponding increase in depreciation and amortization expense; and
- (c) Recording and subsequent write-off of acquired in-process research and development.

Three Months Ended December 31, 2007 compared to the Three Months Ended December 31, 2006

Results for the three months ended December 31, 2007 compared to the three months ended December 31, 2006 are as follows:

	Successor	Predecessor		
	Three Months ended December 31, 2007	Three Months Ended December 31, 2006	Increase/ (Decrease)	
<u>(in millions)</u>			\$	%
Net revenue	\$ 464.0	\$ 416.5	\$ 47.5	11
Cost of products sold	356.4	309.5	46.9	15
Gross margin	107.6	107.0	0.6	1
Selling, general and administrative expenses	84.2	73.8	10.4	14
Impairment charges and (gain)/loss on sale of asset	-	0.9	(0.9)	(100)
Restructuring and other special items	9.0	5.9	3.1	53
Operating earnings	14.4	26.4	(12.0)	(45)
Interest expense, net	52.0	1.0	51.0	*
Other, net	10.6	(0.2)	10.8	*
Earnings/(loss) from continuing operations before income taxes and minority interest	(48.2)	25.6	(73.8)	*
Income tax (benefit)/expense	(19.6)	(4.1)	(15.5)	*
Minority interest (income)/expense, net of tax	0.6	2.0	(1.4)	(70)
Earnings/(loss) from continuing operations	(29.2)	27.7	(56.9)	*
Loss from discontinued operations, net of tax	(1.0)	(9.2)	8.2	(89)
Net earnings/(loss)	\$ (30.2)	\$ 18.5	\$ (48.7)	*

* Percentage not meaningful

Net Revenue

Net revenue increased 11% or \$47.5 million compared to the same period a year ago, primarily due to increased volumes and throughput within our Sterile Technologies segment, including increased output from our new sterile facility in Belgium, as well as strong demand for Oral Technologies pharmaceutical products. The weaker U.S. dollar favorably impacted our revenue growth by approximately 6 percentage points, or \$26.7 million.

Gross Margin

Gross margin increased by 1% or \$0.6 million compared to fiscal 2007. The gross margin for the three months ended December 31, 2007 included a non cash inventory charge and other adjustments of approximately \$11.0 million within our Oral Technologies segment. See Note 1 to the financial statements for further discussion. Excluding these inventory and other adjustments, gross margin increased by 11% or \$11.6 million.

The gross margin increase of 11% was primarily due to increased revenues and improved utilization at our sterile facilities. In addition, our operation excellence program improved throughput and increased production efficiencies, particularly within our Zydis® operation. The weaker U.S. dollar favorably impacted our gross margin by approximately 6 percentage points, or \$6.1 million.

Selling, General and Administrative expense

Selling, general and administrative expenses increased by approximately 14%, or \$10.4 million compared to the comparable period in the prior year. Selling, general and administrative expenses include additional depreciation and amortization expenses of approximately \$10.1 million associated with the intangibles recorded in connection with the Acquisition and the increase in the value of property, plant and equipment recorded as part of the Acquisition. In addition, the weaker U.S. dollar increased our selling, general and administrative expenses by \$3.2 million compared to the comparable period of the prior year.

Excluding these fair value adjustments and the impact of foreign exchange rates, selling, general and administrative expenses decreased by \$2.8 million, or 4%, due to the following:

- Higher allocation of costs by Cardinal by approximately \$4.8 million in the three months ended December 31, 2006 compared to the stand alone costs during the three months ended December 31, 2007,
- A \$3.6 million reduction in equity compensation charges in the three months ended December 31, 2007 compared to the comparable period in the prior year, and
- A decrease in salary costs as a result of the reduction in force that was completed in the quarter ending June 30, 2007.

These favorable factors were offset by increased research and development investment of approximately \$2.1 million and the Sponsor advisory fee of \$2.5 million recorded during the three months ended December 31, 2007.

Restructuring and Other Special Items

Restructuring and other special items increased by \$3.1 million to \$9.0 million for the three months ended December 31, 2007 compared to the three months ended December 31, 2006, of \$5.9 million. The increased charges during the three months ended December 31, 2007 primarily relate to the lease termination costs recorded related to the previously announced closure of one of our Sterile Technologies manufacturing facilities. The closure was finalized during December 2007.

Interest Expense, net

Interest expense, net increased by \$51.0 million for the three months ended December 31, 2007, primarily as a result of the interest expense on our new debt issuances used to finance the Acquisition on April 10, 2007.

Other, net

Other, net increased by \$10.8 million for the three months ended December 31, 2007, primarily as a result foreign currency translation expense recorded related to intercompany loans denominated in non U.S. dollar currency. As these intercompany loans are temporary loans, the impact of translating these loans to U.S. dollar equivalent is recorded in the statement of operations.

Provision/(Benefit) for Income Taxes

Our effective tax rate reflects tax benefits derived from operations outside the United States, which are generally taxed at rates lower than the U.S. statutory rate of 35%. Our three months ended December 31, 2007 benefit for income taxes was (\$19.6) million and relative to losses before income taxes of (\$48.2) million. The benefit for income taxes relative to earnings/(loss) before income taxes, minority interest and discontinued operations was 40.9% and 16.0% for the three months ended December 31, 2007 and December 31, 2006, respectively. Generally, fluctuations in the effective tax rate are primarily due to change in our geographic pretax income resulting from our business mix and changes in the tax impact of restructuring and other special items and other discrete tax items, which may have unique tax implications depending on the nature of the item. The benefit for the three months ended December 31, 2007, includes adjustments in the Company's deferred tax liabilities for tax rate changes in Italy of \$0.4 million.

Segment Review

Our results on a segment basis for the three months ended December 31, 2007 compared to the three months ended December 31, 2006.

	Successor	Predecessor		
	Three Months Ended December 31, 2007	Three Months Ended December 31, 2006	Increase/ (Decrease)	
			\$	%
(in millions)				
Oral Technologies				
Net revenue	\$256.9	\$ 230.6	\$ 26.3	11
Segment EBITDA	50.5	55.5	(5.0)	(9)
Sterile Technologies				
Net revenue	74.1	60.7	13.4	22
Segment EBITDA	4.6	0.4	4.2	*
Packaging Services				
Net revenue	143.7	134.7	9.0	7
Segment EBITDA	19.7	18.1	1.6	9
Inter-segment revenue elimination	(10.7)	(9.5)	(1.2)	13
Unallocated costs ⁽¹⁾	(30.0)	(24.9)	(5.1)	20
Combined Total				
Net revenue	464.0	416.5	47.5	11
EBITDA from continuing operations	\$ 44.8	\$ 49.1	\$ (4.3)	(9)

* Percentage not meaningful

- (1) Unallocated costs includes special items, equity-based compensation, impairment charges, certain other Corporate directed costs, and other costs that are not allocated to the segments as follows:

	Successor	Predecessor
	Three Months Ended December 31, 2007	Three Months Ended December 31, 2006
Impairment charges and gain/(loss) on sale of assets	\$ -	\$ (0.9)
Equity compensation	(2.2)	(5.8)
Restructuring and other special items	(9.0)	(5.9)
Sponsor advisory fee	(2.5)	-
Minority interest, net	(0.6)	(2.0)
Other, net	(10.6)	0.2
Non-allocated corporate costs, net	(5.1)	(10.5)
Total unallocated costs	\$ (30.0)	\$ (24.9)

Provided below is a reconciliation of EBITDA to earnings/(loss) from continuing operations:

(in millions)	<u>Successor</u> <u>Three Months</u> <u>Ended</u> <u>December 31,</u> <u>2007</u>	<u>Predecessor</u> <u>Three Months</u> <u>Ended</u> <u>December 31,</u> <u>2006</u>
EBITDA	\$ 44.8	\$ 49.1
Depreciation and amortization	(41.6)	(24.5)
Interest expense, net	(52.0)	(1.0)
Benefit for income taxes	19.6	4.1
Earnings/(loss) from continuing operations	<u>\$ (29.2)</u>	<u>\$ 27.7</u>

Oral Technologies segment

Net revenues increased by 11% or \$26.3 million primarily due to increased demand for oral pharmaceutical products, particularly products in our controlled release and Zydis ® formats. The increased demand was driven by a mix of new customer products as well as increased volumes on existing customer products. The weaker U.S. dollar favorably impacted the Oral Technologies segment's revenue growth by approximately 7 percentage points, or \$17.2 million.

Segment EBITDA decreased by 9%, or \$5.0 million. During the three months ended December 31, 2007, one of our European manufacturing facilities recorded a non cash inventory charge and other adjustments of approximately \$11.0 million. See Note 1 to the financial statements for further discussion. In addition, the Oral Technologies segment's EBITDA was favorably impacted by the weaker U.S. dollar by approximately 5 percentage points or \$2.8 million. Excluding the impact of these items, the Oral Technologies segment's EBITDA increased by 6%, or \$3.2 million primarily due to an increased number of units sold within the controlled release and Zydis® businesses.

Sterile Technologies segment

Net revenues increased by 22% or \$13.4 million, due to increased volumes at the majority of the sterile manufacturing facilities, including increased demand for flu vaccine products manufactured at our new pre-filled syringe facility, in Belgium. The weaker U.S. dollar favorably impacted the Sterile Technologies segment's revenue growth by approximately 5 percentage points, or \$2.9 million.

Segment EBITDA increased by \$4.2 million primarily due to increased revenues and improved utilization of our sterile facilities, including the ramp-up of our new sterile facility in Belgium. The weaker U.S. dollar favorably impacted the Sterile Technologies segment's EBITDA growth by approximately \$0.4 million.

Packaging Services segment

Net revenues increased by 7%, or \$9.0 million, the weaker U.S. dollar favorably impacted our Packaging Services segment's revenue growth by approximately 4 percentage points or \$5.9 million; excluding this benefit, the revenues increased slightly. Volumes within our European facilities increased, but this increase was offset by lower volumes for North American packaging and printed components.

Segment EBITDA increased by 9%, or \$1.6 million, primarily due to the net revenue increase offset by lower production levels within the North American packaging and printing facilities. Segment EBITDA was also favorably impacted by the weaker U.S. dollar by approximately 6 percentage points, or \$1.0 million.

Six Months Ended December 31, 2007 compared to The Six Months Ended December 31, 2006

Results for the six months ended December 31, 2007 compared to the six months ended December 31, 2006 are as follows:

	Successor		Predecessor	
	Six Months ended December 31, 2007	Six Months Ended December 31, 2006	Increase/ (Decrease)	
			\$	%
<u>(in millions)</u>				
Net revenue	\$ 902.0	\$ 815.0	\$ 87.0	11
Cost of products sold	689.4	621.4	68.0	11
Gross margin	212.6	193.6	19.0	10
Selling, general and administrative expenses	158.5	148.1	10.4	7
Impairment charges and (gain)/loss on sale of asset	0.4	3.1	(2.7)	(87)
Restructuring and other special items	13.3	8.0	5.3	66
Operating earnings	40.4	34.4	6.0	17
Interest expense, net	101.3	2.6	98.7	*
Other, net	19.8	-	19.8	*
Earnings/(loss) from continuing operations before income taxes and minority interest	(80.7)	31.8	(112.5)	*
Income tax (benefit)/expense	(44.0)	(3.8)	(40.2)	*
Minority interest (income)/expense, net of tax	0.3	2.2	(1.9)	(86)
Earnings/(loss) from continuing operations	(37.0)	33.4	(70.4)	*
Loss from discontinued operations, net of tax	(4.5)	(13.8)	9.3	(67)
Net earnings/(loss)	\$ (41.5)	\$ 19.6	\$(61.1)	*

* Percentage not meaningful

Net Revenue

Net revenue increased 11% or \$87.0 million primarily due to strong demand for Oral Technologies pharmaceutical products and increased volumes and throughput within our Sterile Technologies segment, including increased output from our new sterile facility in Belgium. The weaker U.S. dollar favorably impacted our revenue growth by approximately 6 percentage points or \$45.1 million, partially offset by lower volumes of low margin comparator drug sales within the Packaging Services segment, and lower volumes of North American packaging and printed products.

Gross Margin

Gross margin increased by 10%, or \$19.0 million compared to the six months ended December 31, 2006. The gross margin for the six months ended December 31, 2007 included a non cash inventory charge and other adjustments of approximately \$11.0 million within our Oral Technologies segment. See Note 1 to the financial statements for further discussion. Excluding these inventory and other adjustments, gross margin increased by 15% or \$30.0 million.

The gross margin increase of 15% was primarily due to increased revenues and improved utilization at our sterile facilities. In addition, our operation excellence program improved throughput and increased production efficiencies, particularly within our Zydis® operation. The weaker U.S. dollar favorably impacted our gross margin by approximately 5 percentage points or \$10.4 million.

Selling, General and Administrative expense

Selling, general and administrative expenses increased by approximately 7%, or \$10.4 million compared to the comparable period in the prior year. Selling, general and administrative expenses include additional depreciation and amortization expenses of approximately \$20.3 million associated with the intangibles recorded in connection with the Acquisition and the increase in the value of property, plant and equipment recorded as part of the Acquisition. In addition, the weaker U.S. dollar increased our selling, general and administrative expenses by \$5.2 million compared to the comparable period of the prior year. Excluding these fair value adjustments and the impact of foreign exchange rates, selling, general and administrative expenses

decreased by \$15.1 million or 10% due to the following:

- higher allocation of costs by Cardinal by approximately \$10.9 million in the six months ended December 31, 2006 compared to the stand alone costs during the six months ended December 31, 2007,
- a \$9.4 million reduction in equity compensation charges from the fiscal 2006 period to the fiscal 2007 period, and
- a decrease in salary costs as a result of the reduction in force that was completed in the quarter ending June 30, 2007.

These favorable factors were offset by increased in research and development investments of approximately \$2.1 million and the Sponsor advisory fee of \$5.0 million recorded during the six months ended December 31, 2007.

Impairment Charges and (Gain)/Loss on Sale of Asset

Impairment charges and (gain)/loss on sale of assets decreased by \$2.7 million during the six months ended December 31, 2007 compared to the six months ended December 31, 2006. During the six months ended December 31, 2006, we recorded an asset impairment of \$1.8 million based upon a discounted cash flow analysis based upon change in our expected use of the assets related to the Sterile Technologies segment. During the six months ended December 31, 2007, we did not record any significant asset impairment charges.

Restructuring and Other Special Items

Restructuring and other special items increased by \$5.3 million to \$13.3 million for the six months ended December 31, 2007 compared to the six months ended December 31, 2006, of \$8.0 million. The increased charges in during the six months ended December 31, 2007 primarily relate to the lease termination costs recorded related to the previously announced closure of one of our Sterile Technologies manufacturing facilities, as well as additional separation costs incurred as a result of the Acquisition.

Interest Expense, net

Interest expense, net increased by \$98.7 million for the six months ended December 31, 2007, primarily as a result of the interest expense on our new debt issuances used to finance the Acquisition on April 10, 2007.

Other, net

Other, net increased by \$19.8 million for the six months ended December 31, 2007, primarily as a result foreign currency translation expense recorded related to intercompany loans denominated in non U.S. dollar currency. As these intercompany loans are not permanently reinvested temporary loans, the impact of translating these loans to U.S. dollar equivalent is recorded in the statement of operations.

Provision/(Benefit) for Income Taxes

Our effective tax rate reflects tax benefits derived from operations outside the United States, which are generally taxed at rates lower than the U.S. statutory rate of 35%. Our six months ended December 31, 2007 benefit for income taxes was (\$44.0) million and relative to losses before income taxes of (\$80.7) million. The benefit for income taxes relative to earnings/(loss) before income taxes, minority interest and discontinued operations was 54.6% and 12.0% for the six months ended December 31, 2007 and December 31, 2006, respectively. Generally, fluctuations in the effective tax rate are primarily due to change in our geographic pretax income resulting from our business mix and changes in the tax impact of restructuring and other special items and other discrete tax items, which may have unique tax implications depending on the nature of the item. The benefit for the six months ended December 31, 2007, includes adjustments in the Company's deferred tax liabilities for tax rate changes in Germany, UK, and Italy of \$5.5 million, \$3.9 million and \$0.4million, respectively.

Segment Review

Our results on a segment basis for the six months ended December 31, 2007 compared to the six months ended December 31, 2006.

	Successor	Predecessor		
	Six Months Ended December 31, 2007	Six Months ended December 31, 2006	Increase/ (Decrease)	
			\$	%
(in millions)				
Oral Technologies				
Net revenue	\$ 492.1	\$ 447.0	45.1	10
Segment EBITDA	99.9	97.6	2.3	2
Sterile Technologies				
Net revenue	144.6	116.6	28.0	24
Segment EBITDA	10.7	(4.7)	15.4	*
Packaging Services				
Net revenue	285.4	272.5	12.9	5
Segment EBITDA	40.5	35.1	5.4	15
Inter-segment revenue elimination	(20.1)	(21.1)	1.0	(5)
Unallocated costs ⁽¹⁾	(48.5)	(47.5)	(1.0)	2
Combined Total				
Net revenue	\$ 902.0	\$ 815.0	87.0	11
EBITDA from continuing operations	102.6	80.5	22.1	27

* Percentage not meaningful

- (1) Unallocated costs includes special items, equity-based compensation, impairment charges, certain other Corporate directed costs, and other costs that are not allocated to the segments as follows:

	Successor	Predecessor
	Six Months Ended December 31, 2007	Six Months Ended December 31, 2006
Impairment charges and gain/(loss) on sale of assets	\$ (0.4)	\$ (3.1)
Equity compensation	(4.0)	(13.4)
Restructuring and other special items	(13.3)	(8.0)
Sponsor advisory fee	(5.0)	-
Minority interest, net	(0.3)	(2.2)
Other, net	(19.8)	-
Non-allocated corporate costs, net	(5.7)	(20.8)
Total unallocated costs	\$ (48.5)	\$ (47.5)

Provided below is a reconciliation of EBITDA to earnings/(loss) from continuing operations:

(in millions)	Successor Six Months Ended December 31, 2007	Predecessor Six Months Ended December 31, 2006
EBITDA	\$ 102.6	\$ 80.5
Depreciation and amortization	(82.3)	(48.3)
Interest expense, net	(101.3)	(2.6)
Benefit/(provision) for income taxes	44.0	3.8
Earnings/(loss) from continuing operations	\$ (37.0)	\$ 33.4

Oral Technologies segment

Net revenues increased by 10%, or \$45.1 million primarily due to increased demand for oral pharmaceutical products, particularly products in our controlled release and Zydis ® formats. The increased demand was driven by a mix of new customer products as well as increased volumes on existing customer products. These increases were partially offset by the sale of an Oral Technologies facility in July 2006, which reduced revenue by \$7.0 million in the six months ended December 31, 2007 compared to the corresponding period in 2006. The weaker U.S. dollar favorably impacted the Oral Technologies segment's revenue growth by approximately 6 percentage points, or \$28.9 million.

Segment EBITDA increased slightly by 2%, or \$2.3 million. During the six months ended December 31, 2007, one of our European manufacturing facilities recorded a non cash inventory charge and other adjustments of approximately \$11.0 million. See Note 1 to the financial statements for further discussion. In addition, the segment's EBITDA was favorably impacted by the weaker U.S. dollar by approximately 5 percentage points, or \$5.1 million. Excluding the impact of these items, Oral Technologies segment's EBITDA increased by approximately 8% or \$8.2 million primarily due to increased sales within the controlled release and Zydis® businesses.

Sterile Technologies segment

Net revenues increased by 24%, or \$28.0 million, due to increased volumes at the majority of the sterile manufacturing facilities, including increased demand for flu vaccine products manufactured at our new pre-filled syringe facility in Belgium. The weaker U.S. dollar favorably impacted the Sterile Technologies segment's revenue growth by approximately 4 percentage points, or \$4.8 million.

Segment EBITDA increased by \$15.4 million, with EBITDA of \$10.7 million for the six months ended December 31, 2007, compared to a loss of \$4.7 million in the corresponding period in the prior year. The increase was primarily due to increased revenues and improved utilization of our sterile facilities, including the ramp-up of our new facility in Belgium. The weaker U.S. dollar favorably impacted the Sterile Technologies segment's EBITDA growth by approximately \$0.7 million.

Packaging Services segment

Net revenues increased by 5%, or \$12.9 million. The weaker U.S. dollar favorably impacted our Packaging Services segment's revenue growth by approximately 4 percentage points, or \$10.3 million; excluding this benefit, revenues would have been flat. Volumes for European packaging and printing increased, but this increase was offset by reduced volumes of low margin comparator drug sales and lower volumes for North American packaging and printed components.

Segment EBITDA increased by 15%, or \$5.4 million, primarily due to the net revenue increase offset by lower production levels within the North American packaging and printing facilities. Lastly, segment EBITDA was favorably impacted by the weaker U.S. dollar by approximately 5 percentage points, or \$1.8 million.

Liquidity and Capital Resources

Sources and Use of Cash

Our principal source of liquidity has been cash flow generated from operations. The principal uses of cash are to fund planned operating expenditures, capital expenditures, interest rate payments on debt and any mandatory or discretionary principal payments of debt issuances. As of December 31, 2007, our financing needs were supported by \$350 million of available capacity in our revolving credit agreement of which \$30.0 million net of borrowings was utilized as of December 31, 2007.

We continue to believe that our cash from operations and available borrowings under our new revolving credit facility will be adequate to meet our future liquidity needs for at least the next twelve months.

Cash Flows

The following table summarizes our statement of cash flows from continuing operations:

(in millions)	Successor	Predecessor	
	Six Months Ended December 31, 2007	Six Months Ended December 31, 2006	\$ Change
Net cash provided by / (used in)			
Operating activities	\$ (35.1)	\$ 82.5	\$ (117.6)
Investing activities	(37.2)	(21.8)	(15.4)
Financing activities	17.5	(30.3)	47.8

Operating activities

For the six month period ended December 31, 2007, cash used by operating activities was \$35.1 million compared to cash provided by operating activities of \$82.5 million for the six month period ended December 31, 2006. Cash used in operating activities for the fiscal 2008 period was mainly due to interest payments associated with the Acquisition-related debt as well as payment of approximately \$27.2 million for one of the Company's pension plans.

Investing activities

For the six month period ended December 31, 2007, cash used in investing activities was \$37.2 million, an increase of \$15.4 million compared to the six month period ending December 31, 2006, primarily driven by proceeds from the divestiture of an Oral Technologies facility during fiscal 2007 of \$11.7 million.

Financing activities

For the six month period ended December 31, 2007, cash provided by financing activities was \$17.5 million compared to cash used in financing activities of \$30.3 million in the same period a year ago. Cash provided in the fiscal 2008 period was mainly attributable to an equity contribution of \$14.1 million from PTS Intermediate Holdings LLC and short term borrowings of \$15.2 million, partially offset by net repayments of long term debt obligations of \$11.8 million. Cash used in the fiscal 2007 period was mainly due to net transfers to Cardinal.

Debt and Financing Arrangements

As of December 31, 2007, the Company had \$30.0 million outstanding of net borrowings under its Revolving Credit Agreement. As of December 31, 2007, the Company entered into interest rate swaps, expiring June 2010, as a derivative instrument to manage the risk associated with the Company's floating rate debt. The unrealized loss on the hedge instruments of \$17.2 million is recorded within Accumulated Other Comprehensive Income on the Company's consolidated condensed balance sheet at December 31, 2007.

As of December 31, 2007, the Company was in compliance with all restrictive covenants related to its long-term obligations.

Guarantees and Security

All obligations under the senior secured credit agreement, the senior toggle notes and the senior subordinated notes are unconditionally guaranteed by each of the Company's existing U.S. wholly owned subsidiaries, other than the Company's Puerto Rico subsidiaries, subject to certain exceptions.

All obligations under the senior secured credit facilities, and the guarantees of those obligations, are secured by substantially all the following assets of the Company and each guarantor, subject to certain exceptions:

- a pledge of 100% of the capital stock of the Company and 100% of the equity interests directly held by Company and each guarantor in any wholly-owned material subsidiary of the Company or any guarantor (which pledge, in the case of any non-U.S. subsidiary of a U.S. subsidiary, will not include more than 65% of the voting stock of such non-U.S. subsidiary); and
- a security interest in, and mortgages on, substantially all tangible and intangible assets of Company and each guarantor, subject to certain limited exceptions.

During the six months ended December 31, 2007, our non-guarantor subsidiaries accounted for approximately \$568.9 million, or approximately 63.1%, of our total net revenue, and approximately \$64.8 million, or approximately 63.2%, of our total EBITDA from continuing operations of \$102.6 million.

As of December 31, 2007, our non-guarantor subsidiaries accounted for approximately \$1.3 billion, or 56.3%, of our total assets (excluding intercompany receivables and goodwill), and approximately \$360.4 million, or 63.8%, of our total liabilities (excluding intercompany liabilities and issuer's debt of approximately \$2.4billion).

Debt Covenants

The senior secured credit agreement and the indentures governing the Senior Toggle Notes and the Senior Subordinated Notes contain a number of covenants that, among other things, restrict, subject to certain exceptions, the Company's (and the Company's restricted subsidiaries') ability to incur additional indebtedness or issue certain preferred shares; create liens on assets; engage in mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; engage in certain transactions with affiliates; make investments, loans or advances; make certain acquisitions; and in the case of the Company's senior credit agreement, enter into sale and leaseback transactions; repay subordinated indebtedness, amend material agreements governing the Company's subordinated indebtedness (including the senior subordinated notes); and change the Company's lines of business.

Subject to certain exceptions, the senior credit agreement and the indentures governing the notes will permit the Company and its restricted subsidiaries to incur additional indebtedness, including secured indebtedness. None of our non-U.S. subsidiaries or Puerto Rico subsidiaries are guarantors of the loans or notes.

As market conditions warrant and subject to our contractual restrictions and liquidity position, we and/or our major equityholders, including Blackstone and its affiliates, may from time to time repurchase our outstanding debt securities, including the Senior Toggle Notes and the Senior Subordinated Notes; and/or our outstanding bank loans, in privately negotiated or open market transactions, by tender or otherwise. Any such repurchases may be funded by incurring new debt, including additional borrowings under our existing revolving credit facility. Any new debt may also be secured debt. We may also use available cash on our balance sheet.

Historical and Adjusted EBITDA

Adjusted EBITDA is based on the definitions in our indentures, is not defined under U.S. GAAP, and is subject to important limitations.

In calculating Adjusted EBITDA, we add back certain non-cash, non-recurring and other items that are included in EBITDA and net income as required by various covenants in the indentures governing the notes. Adjusted EBITDA, among other things:

- does not include non-cash stock-based employee compensation expense and certain other non-cash charges;
- does not include cash and non-cash restructuring, severance and relocation costs incurred to realize future cost savings and enhance our operations;
- adds back minority interest expense, which represents the minority investors' ownership of certain of our consolidated subsidiaries and is, therefore not available to us; and
- includes estimated cost savings which have not yet been fully reflected in our results.

Our Combined Adjusted EBITDA for the trailing twelve months ended December 31, 2007 based on the definitions in our indentures is calculated as follows:

(in millions)

	Successor	Successor	Predecessor	Combined
	Six Months	April 10, 2007	January 1, 2007	Twelve Months
	Ended	To	to	Ended
	December 31, 2007	June 30, 2007	April 9, 2007	December 31, 2007
Earnings/(loss) from continuing operations	\$ (37.0)	\$ (147.0)	\$ 4.0	\$ (180.0)
Interest expense, net	101.3	44.1	6.3	151.7
Benefit for income taxes	(44.0)	(21.2)	1.8	(63.4)
Depreciation and amortization	82.3	37.2	29.3	148.8
EBITDA	<u>\$ 102.6</u>	<u>\$ (86.9)</u>	<u>\$ 41.4</u>	57.1
Equity compensation ⁽¹⁾				26.7
Impairment charges and (gain)/loss on sale of assets ⁽²⁾				(4.2)
Restructuring and other special items ⁽³⁾				194.5
Other non-recurring/one-time items ⁽⁴⁾				26.0
Estimated cost savings ⁽⁵⁾				21.7
Other adjustments ⁽⁶⁾				6.0
Sponsor monitoring fee ⁽⁷⁾				7.2
Disposition adjustments ⁽⁸⁾				3.9
Adjusted EBITDA				<u>\$ 338.9</u>

⁽¹⁾ Reflects non-cash stock-based employee compensation expense under the provisions of SFAS No. 123R, *Share-based Payments*.

⁽²⁾ Reflects non-cash asset impairment charges and losses from the sale of assets not included in restructuring and special items discussed below.

⁽³⁾ Restructuring and other special charges of \$194.5 million included \$175.4 million of non-cash charges. The total \$194.5 reflects the following:

- \$17.4 million related to restructuring activities, which includes \$9.5 million of employee-related costs. The restructuring programs focus on various aspects of operations, including closing and consolidation of certain operations, rationalizing headcount and aligning operations in a more strategic and cost-efficient structure.
- \$20.9 million of retention bonuses associated with the Acquisition that will not have a continuing impact.

- \$13.7 million related costs incurred to separate from Cardinal.
 - \$141.8 million associated with the fair value adjustments to the balance sheet as a result of the Acquisition, including higher inventory costs during the period April 10, 2007 to June 30, 2007 of \$29.4 million and the write off of In-process research and development of \$112.4 million.
 - \$0.7 million associated with amortization of a non-compete agreement associated with an acquisition by the Predecessor.
- (4) Reflects the following one-time items: \$9.1 million associated with start-up investment in our new Sterile Technologies facilities in Brussels and North Raleigh, \$10.0 million related to the one-time non cash inventory write down within our Oral Technologies segment (see Note 1 to the financial statements) and \$6.9 million of other non-recurring items. Although we refer to these as one-time items, there can be no guarantee that we will not incur similar items in the future.
- (5) Reflects cost savings that we estimate we would have achieved from our restructuring and operational excellence programs where actions have begun or have already been completed if those actions had been completed at the beginning of the period presented, including \$4.7 million from headcount reductions and \$17.0 million from other cost reduction initiatives. However, there is no guarantee we will be able to achieve this level of cost savings.
- (6) Reflects other adjustments required in calculation our covenant compliance under the indentures governing our notes, primarily \$2.7 million of minority interest expense, \$1.9 million of severance and relocation costs and \$0.4 million of franchise taxes in selling, general and administrative expenses. However, minority interest expense does not represent EBITDA that is available to us, and we expect to incur severance and relocation costs and franchise taxes in the future. In addition, other adjustments reflect the estimated decrease to pension and post-retirement benefits expense resulting from the elimination of amortization and deferral of unrecognized actuarial losses and prior service costs of \$0.8 million associated with the purchase accounting related to the Acquisition. Lastly, other adjustments reflect the rent expense that has been eliminated of \$0.2 million and replaced by comparable amounts of depreciation expense when we purchased, in January 2007, the buildings and equipment that were previously under an operating lease.
- (7) Represents amount of sponsor monitoring fee. See Note 10 to the financial statements.
- (8) Reflects the elimination of \$3.8 million of losses from one of our facilities, which we closed in December 2007, plus \$0.1 million of EBITDA generated by businesses which we sold on March 9, 2007. We have not eliminated \$1.9 million of EBITDA generated by an Oral Technologies facility which was sold to a customer in July 2006, because it is part of a larger customer relationship that is expected to continue. We cannot assure you that this customer will continue to generate the same level of cash flows as in the past.

Interest Rate Risk Management

A portion of the debt used to finance our operations is exposed to interest rate fluctuations. We may use various hedging strategies and derivative financial instruments to create an appropriate mix of fixed and floating rate assets and liabilities. The primary interest rate exposure as of December 31, 2007 is to interest rate fluctuations in the United States and Europe, especially LIBOR and EURIBOR interest rates. We currently use interest rate swaps as the derivative instrument in these hedging strategies. The derivatives used to manage the risk associated with our floating rate debt were designated as cash flow hedges.

Currency Rate Risk Management

Periodically we may utilize forward currency exchange contracts to manage our exposures to the variability of cash flows primarily related to the foreign exchange rate changes of future foreign currency transaction costs. In addition, from time to time we will utilize foreign currency forward contracts to protect the value of existing foreign currency assets and liabilities. We expect to continue to evaluate hedging opportunities for foreign currency in the future.

Contractual Obligations

Our future contractual obligations have not changed significantly from the amounts reported within our fiscal 2007 Consolidated and Combined Financial Statements. Any changes to our obligations related to our indebtedness are presented above within the section entitled "Debt and Financing Arrangements".

Off-Balance Sheet Arrangements

Other than operating leases, we do not have any off-balance sheet arrangements as of December 31, 2007.

Quantitative and Qualitative Disclosures About Market Risk

We do not believe that there has been a material change to the quantitative and qualitative market risks disclosed in our fiscal 2007 Consolidated and Combined Financial Statements.